<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Anaesth</journal-id><journal-id journal-id-type="iso-abbrev">Br J Anaesth</journal-id><journal-id journal-id-type="pmc-domain-id">718</journal-id><journal-id journal-id-type="pmc-domain">brjana</journal-id><journal-title-group><journal-title>BJA: British Journal of Anaesthesia</journal-title></journal-title-group><issn pub-type="ppub">0007-0912</issn><issn pub-type="epub">1471-6771</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12106897</article-id><article-id pub-id-type="pmcid-ver">PMC12106897.1</article-id><article-id pub-id-type="pmcaid">12106897</article-id><article-id pub-id-type="pmcaiid">12106897</article-id><article-id pub-id-type="pmid">40113476</article-id><article-id pub-id-type="doi">10.1016/j.bja.2025.02.012</article-id><article-id pub-id-type="pii">S0007-0912(25)00114-X</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pain</subject></subj-group></article-categories><title-group><article-title>Multimorbidity and analgesic-related harms: a systematic review</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Grant</surname><given-names initials="CH">Christopher H.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Walker</surname><given-names initials="H">Heather</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Barnett</surname><given-names initials="KN">Karen N.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Mark</surname><given-names initials="PB">Patrick B.</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Colvin</surname><given-names initials="LA">Lesley A.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Bell</surname><given-names initials="S">Samira</given-names></name><email>s.t.bell@dundee.ac.uk</email><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://twitter.com/@SamiraBell76"><inline-graphic xlink:href="fx1.gif"><alt-text id="at001">Twitter icon</alt-text></inline-graphic>@SamiraBell76</ext-link><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><aff id="aff1"><label>1</label>Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, UK</aff><aff id="aff2"><label>2</label>School of Cardiovascular and Metabolic Health, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding author. <email>s.t.bell@dundee.ac.uk</email><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://twitter.com/@SamiraBell76"><inline-graphic xlink:href="fx1.gif"><alt-text>Twitter icon</alt-text></inline-graphic>@SamiraBell76</ext-link></corresp></author-notes><pub-date pub-type="ppub"><month>6</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>20</day><month>3</month><year>2025</year></pub-date><volume>134</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">489277</issue-id><fpage>1717</fpage><lpage>1745</lpage><history><date date-type="received"><day>1</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>15</day><month>2</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>03</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>05</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-05-29 14:25:15.877"><day>29</day><month>05</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s)</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><sec><title>Background</title><p>Multimorbidity is the presence of two or more long-term medical conditions. Chronic pain affects more than half of people with multimorbidity, and optimal treatment strategies are unknown. We aimed to quantify the risk of adverse outcomes from the following analgesics: opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and gabapentinoids in adults with multimorbidity.</p></sec><sec><title>Method</title><p>The review was registered on PROSPERO (CRD42023462592). We searched Medline, CINAHL, Web of Science, Embase, and CENTRAL for studies reporting analgesic-related harms in people with multimorbidity or the impact of multimorbidity on harms in adults exposed to analgesics. Two researchers independently screened titles/abstracts, completed full-text reviews, extracted data, and assessed risk of bias using the Newcastle-Ottawa scale. Studies were synthesised narratively, grouping by analgesic class and direction of effect.</p></sec><sec><title>Results</title><p>We screened 6690 records and 344 full texts, with 27 studies included (<italic toggle="yes">n</italic>=2 671 958 patients). Studies were heterogenous, with variable quality (high risk of bias, <italic toggle="yes">n</italic>=11). Most studies on opioids reported adverse outcomes (12/16). Opioid use compared with non-use was associated with increased mortality in adults with multimorbidity. Multimorbidity was associated with opioid overdose and death among adults prescribed opioids for pain. Half of studies of NSAIDs reported adverse outcomes (6/11) including gastrointestinal bleeding. Only one study assessed gabapentinoids which found an association with delirium and pneumonia, but not mortality in people with multimorbidity.</p></sec><sec><title>Conclusions</title><p>There is evidence of harms associated with opioids in adults with multimorbidity, including overdose and increased mortality. There is a lack of evidence on gabapentinoids. Further research is required to understand optimal analgesic management in people with multimorbidity.</p></sec><sec><title>Systematic review protocol</title><p>PROSPERO (CRD42023462592).</p></sec></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>analgesics</kwd><kwd>drug-related harms</kwd><kwd>multiple long-term conditions</kwd><kwd>multimorbidity</kwd><kwd>opioids</kwd><kwd>serious adverse effects</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta><notes><p id="misc0010">Handling Editor: Jonathan Hardman</p></notes></front><body><p id="p0010">
<boxed-text id="dtbox1" position="float" orientation="portrait"><caption><title>Editor's key points</title></caption><p id="p0015">
<list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#8226;</label><p id="p0020">Chronic pain affects more than half of people with multimorbidity (more than one long-term condition). Optimal analgesic strategies are unknown. Such patients are under-represented in trials.</p></list-item><list-item id="u0015"><label>&#8226;</label><p id="p0025">This review article summarises the available evidence on&#160;analgesic-related harms in adults with multimorbidity. There is evidence of harm associated&#160;with opioid use, including overdose and mortality,&#160;and an absence of evidence related to gabapentinoids.</p></list-item><list-item id="u0020"><label>&#8226;</label><p id="p0030">Caution should be exercised when prescribing opioids to multimorbid patients. Further research is needed to quantify the benefits and harms of analgesics, specifically NSAIDs and gabapentinoids.</p></list-item></list>
</p></boxed-text>
</p><p id="p0035">Multimorbidity is the presence of two or more long-term physical or mental health conditions<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> and affects more than a third of adults worldwide.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> Multimorbidity increases with age and socioeconomic deprivation and is associated with reduced quality of life and premature mortality.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref> Furthermore, multimorbidity represents a major challenge for global health care systems, which are orientated towards disease-specific management.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="bib9" ref-type="bibr"><sup>9</sup></xref></p><p id="p0040">Chronic pain affects more than half of people with multimorbidity<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> with limited management options. Guidelines for people with multimorbidity do not make recommendations on the treatment of pain,<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> nor do guidelines on chronic pain management make specific recommendations for people with multimorbidity.<xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref> The prevalence of analgesic use in those with multiple long-term conditions (LTCs) varies by setting (e.g. primary or secondary care) and has been reported to be as many as three in four hospital inpatients.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref></p><p id="p0045">People with multimorbidity are under-represented in clinical trials<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> and so the safety of analgesic use among this population has not been established. Pharmacological treatments for pain are often associated with adverse events. Opioids, gabapentinoids, and nonsteroidal anti-inflammatory drugs (NSAIDs) are three of the most widely prescribed analgesics.<xref rid="bib19" ref-type="bibr">19</xref>, <xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref> Opioids can lead to small reductions in pain intensity, but are also associated with increased risk of overdose, abuse, fractures, and myocardial infarction,<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref><sup>,</sup><xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> with little long-term data on the safety of opioids for chronic non-cancer pain despite widespread use.<xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib28" ref-type="bibr">28</xref> Gabapentinoids have neurological sequelae (e.g. sedation and ataxia) in addition to abuse potential<xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib30" ref-type="bibr">30</xref>, <xref rid="bib31" ref-type="bibr">31</xref>, <xref rid="bib32" ref-type="bibr">32</xref>, <xref rid="bib33" ref-type="bibr">33</xref>, <xref rid="bib34" ref-type="bibr">34</xref> and possible increased mortality.<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> NSAIDs are associated with gastrointestinal complications, acute kidney injury (AKI), and cardiovascular events.<xref rid="bib36" ref-type="bibr">36</xref>, <xref rid="bib37" ref-type="bibr">37</xref>, <xref rid="bib38" ref-type="bibr">38</xref>, <xref rid="bib39" ref-type="bibr">39</xref>, <xref rid="bib40" ref-type="bibr">40</xref> A meta-analysis reporting opioid outcomes found that observational and interventional studies of older adults (&gt;65 yr) excluded those with substantial comorbidities.<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref><sup>,</sup><xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> Although some studies have assessed the impact of comorbid conditions in isolation, there is a lack of studies examining the adverse effects of analgesics in people with multimorbidity. It is likely that the lack of consistency regarding the measurement of multimorbidity has hindered appropriate study<xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>, <xref rid="bib45" ref-type="bibr">45</xref> with recent consensus recommending that multimorbidity be measured by LTC count or weighted comorbidity scoring index, depending on the study purpose.<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref> The harms of analgesics by such measures have received little attention despite most opioid-related hospitalisations occurring in adults with multimorbidity.<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref></p><p id="p0050">The aim of this systematic review was to quantify the risk of adverse outcomes from opioids, NSAIDs, and gabapentinoids in adults with multimorbidity.</p><sec id="sec1"><title>Methods</title><p id="p0055">This systematic review was registered prospectively on PROSPERO (registration number: CRD42023462592). The results are reported with reference to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement.<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref></p><sec id="sec1.1"><title>Eligibility criteria</title><p id="p0060">To be eligible for inclusion, studies had to record and report multimorbidity using a recommended measure (i.e. a weighted comorbidity scoring index or LTC count)<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref> in adults (aged 18 yr or older). Studies involving only people with multimorbidity or where the population was reported to have a mean/median of two or more LTCs and who were exposed to opioids, NSAIDs (non-aspirin) or gabapentinoids for pain, and followed for drug-related harms, were eligible. Studies of general populations that did not report baseline multimorbidity were only eligible if the independent association of a recommended measure of multimorbidity<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref> on adverse events was reported among adults prescribed relevant analgesics for pain. An adverse event related to analgesic use was defined according to the PRISMA harms checklist as &#8216;<italic toggle="yes">an unfavourable outcome that occurs during or after the use of a drug&#8217; for which &#8216;the causal relation between the intervention and the event is at least a reasonable possibility</italic>&#8217;.<xref rid="bib49" ref-type="bibr">49</xref>, <xref rid="bib50" ref-type="bibr">50</xref>, <xref rid="bib51" ref-type="bibr">51</xref> Drug-related harms therefore included any harm reported regardless of whether it was considered serious, that could be potentially related to the consumption of a relevant analgesic. Empirical quantitative studies, including observational and interventional (i.e. whereby investigators actively intervened as part of the study design<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref>), were eligible for inclusion. Studies that did not report a recognised measure of multimorbidity or drug-related harms were excluded. Studies were also excluded if the multimorbidity measure and the relevant analgesic were treated as covariates in a multivariable model such that the relationship of interest could not be isolated. Non-English language, qualitative and non-primary reports (e.g. narrative review articles) were ineligible. Full details of eligibility criteria are listed in <xref rid="appsec1" ref-type="sec">Supplementary material S1</xref>.</p></sec><sec id="sec1.2"><title>Search strategy and study selection</title><p id="p0065">The search strategy was devised with the assistance of an academic librarian (SM), using a combination of index terms and keywords, with reference to Cochrane guidance on identifying studies of adverse effects.<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref> Medline (PubMed), CINAHL (Ebsco), Web of Science, Embase (Ovid), and CENTRAL (Cochrane Library) were searched from inception to September 30, 2024. Records were imported into Covidence software for study selection.<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref> Titles/abstracts were screened and potentially relevant texts sourced for full eligibility assessment by two independent researchers (CHG/HW). Disagreements were resolved by consensus, a third reviewer (SB), or both. The search strategy for all databases is provided in <xref rid="appsec1" ref-type="sec">Supplementary Table&#160;S1</xref>.</p></sec><sec id="sec1.3"><title>Data extraction and risk of bias</title><p id="p0070">A data extraction form was created to record study characteristics (e.g. design, setting, sample size, dates), participants (e.g. inclusion/exclusion criteria, multimorbidity definition/measure, patient characteristics, comorbidities), analgesic exposure (e.g. medication, form, dose, data sources), adverse outcomes (e.g. definition/measure, timing, missing data, loss to follow-up), and statistical method (e.g. analysis, adjustments, censoring).</p><p id="p0075">The Newcastle-Ottawa Scale<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> was used to assess risk of bias in observational studies covering selection, comparability, and outcome/exposure domains with required modifications (<xref rid="appsec1" ref-type="sec">Supplementary material S2</xref>). It has been used in previous reviews of analgesic-related harms<xref rid="bib56" ref-type="bibr"><sup>56</sup></xref><sup>,</sup><xref rid="bib57" ref-type="bibr"><sup>57</sup></xref> and multimorbidity.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> The risk of bias in non-randomised studies of interventions (ROBINS-I)<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref> tool was used to assess bias in interventional studies.</p><p id="p0080">Data from each study were extracted and studies assessed for quality by two independent reviewers (CHG/HW) with discrepancies resolved by consensus, a third reviewer (SB), or both.</p></sec><sec id="sec1.4"><title>Data synthesis</title><p id="p0085">It was expected that statistical synthesis through meta-analyses would not be possible because of substantial methodological and contextual heterogeneity. Studies were therefore grouped into analgesic class for the purposes of synthesis to generate clinically relevant results. Studies were further subdivided based on direction of association/effect (i.e. evidence of harm associated with multimorbidity or analgesic exposure <italic toggle="yes">vs</italic> no evidence of harm) and described according to setting (i.e. secondary care, primary care or both) because of inconsistencies in the effect measures and data reported across studies.<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref> The numerical results included in the synthesis are displayed in tabular form consistent with in-text description.</p></sec></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>Study selection</title><p id="p0090">A systematic search of the literature returned 6690 records. After the removal of duplicates, 4679 titles/abstracts were screened and 344 full texts retrieved for eligibility assessment. A total of 27 studies<xref rid="bib60" ref-type="bibr">60</xref>, <xref rid="bib61" ref-type="bibr">61</xref>, <xref rid="bib62" ref-type="bibr">62</xref>, <xref rid="bib63" ref-type="bibr">63</xref>, <xref rid="bib64" ref-type="bibr">64</xref>, <xref rid="bib65" ref-type="bibr">65</xref>, <xref rid="bib66" ref-type="bibr">66</xref>, <xref rid="bib67" ref-type="bibr">67</xref>, <xref rid="bib68" ref-type="bibr">68</xref>, <xref rid="bib69" ref-type="bibr">69</xref>, <xref rid="bib70" ref-type="bibr">70</xref>, <xref rid="bib71" ref-type="bibr">71</xref>, <xref rid="bib72" ref-type="bibr">72</xref>, <xref rid="bib73" ref-type="bibr">73</xref>, <xref rid="bib74" ref-type="bibr">74</xref>, <xref rid="bib75" ref-type="bibr">75</xref>, <xref rid="bib76" ref-type="bibr">76</xref>, <xref rid="bib77" ref-type="bibr">77</xref>, <xref rid="bib78" ref-type="bibr">78</xref>, <xref rid="bib79" ref-type="bibr">79</xref>, <xref rid="bib80" ref-type="bibr">80</xref>, <xref rid="bib81" ref-type="bibr">81</xref>, <xref rid="bib82" ref-type="bibr">82</xref>, <xref rid="bib83" ref-type="bibr">83</xref>, <xref rid="bib84" ref-type="bibr">84</xref>, <xref rid="bib85" ref-type="bibr">85</xref>, <xref rid="bib86" ref-type="bibr">86</xref> were included in the review. Reasons for exclusions are detailed in <xref rid="fig1" ref-type="fig">Figure&#160;1</xref>.<fig id="fig1" position="float" orientation="portrait"><label>Fig 1</label><caption><p>PRISMA flow diagram. MM, multimorbidity; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.</p></caption><alt-text id="alttext0015">Fig 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p></sec><sec id="sec2.2"><title>Characteristics of included studies</title><p id="p0095">Twenty seven studies included data from 2 671 958 people. A diverse range of methodologies was observed with substantial variability in study design including: setting, population(s), multimorbidity measures, quantification of analgesics, comparisons, and outcomes. Sixteen studies assessed opioids,<xref rid="bib60" ref-type="bibr">60</xref>, <xref rid="bib61" ref-type="bibr">61</xref>, <xref rid="bib62" ref-type="bibr">62</xref>, <xref rid="bib63" ref-type="bibr">63</xref>, <xref rid="bib64" ref-type="bibr">64</xref>, <xref rid="bib65" ref-type="bibr">65</xref>, <xref rid="bib66" ref-type="bibr">66</xref>, <xref rid="bib67" ref-type="bibr">67</xref>, <xref rid="bib68" ref-type="bibr">68</xref>, <xref rid="bib69" ref-type="bibr">69</xref>, <xref rid="bib70" ref-type="bibr">70</xref>, <xref rid="bib71" ref-type="bibr">71</xref>, <xref rid="bib72" ref-type="bibr">72</xref>, <xref rid="bib73" ref-type="bibr">73</xref>, <xref rid="bib74" ref-type="bibr">74</xref><sup>,</sup><xref rid="bib86" ref-type="bibr"><sup>86</sup></xref> 11 examined NSAIDs,<xref rid="bib74" ref-type="bibr">74</xref>, <xref rid="bib75" ref-type="bibr">75</xref>, <xref rid="bib76" ref-type="bibr">76</xref>, <xref rid="bib77" ref-type="bibr">77</xref>, <xref rid="bib78" ref-type="bibr">78</xref>, <xref rid="bib79" ref-type="bibr">79</xref>, <xref rid="bib80" ref-type="bibr">80</xref>, <xref rid="bib81" ref-type="bibr">81</xref>, <xref rid="bib82" ref-type="bibr">82</xref>, <xref rid="bib83" ref-type="bibr">83</xref><sup>,</sup><xref rid="bib85" ref-type="bibr"><sup>85</sup></xref> and one study focused on gabapentinoids.<xref rid="bib84" ref-type="bibr"><sup>84</sup></xref> One study reported results for both opioids and NSAIDs, separately.<xref rid="bib74" ref-type="bibr"><sup>74</sup></xref> Basic descriptors of included studies are summarised in <xref rid="tbl1" ref-type="table">Table&#160;1</xref>.<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p>Basic descriptors of included studies, <italic toggle="yes">n</italic>=27. ACG, adjusted clinical group; ADG, aggregated diagnosis group; AKI, acute kidney injury; CCI, Charlson Comorbidity Index; CV, cardiovascular; ECI, Elixhauser comorbidity index; ED, emergency department; GI, gastrointestinal; HAM-D 17, Hamilton Depression Rating Scale; HbA1C, haemoglobin A1c; HIV, human immunodeficiency virus; LOS, length of stay; LTC, long-term condition; MM, multimorbidity; MMSE, mini-mental state exam; NSAID, nonsteroidal anti-inflammatory drugs; N/R, not reported; OA, osteoarthritis; ORADE, opioid-related adverse drug event; rDANCAMI score, Danish Comorbidity Index for Acute Myocardial Infarction restricted to non-cardiovascular diseases; SF-12, Short Form-12 survey; TMA, thrombotic microangiopathy. &#8727;Individually reported.</p></caption><alt-text id="alttext0020">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Reference</th><th colspan="1" rowspan="1">Country</th><th colspan="1" rowspan="1">Study design</th><th colspan="1" rowspan="1">Study dates</th><th colspan="1" rowspan="1">Setting</th><th colspan="1" rowspan="1">Population</th><th colspan="1" rowspan="1">MM measure</th><th colspan="1" rowspan="1">Analgesic(s)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Podesser and colleagues, 2024<xref rid="bib86" ref-type="bibr"><sup>86</sup></xref></td><td colspan="1" rowspan="1">Austria</td><td colspan="1" rowspan="1">Case control</td><td colspan="1" rowspan="1">June 2016&#8211;March 2018</td><td colspan="1" rowspan="1">Secondary</td><td colspan="1" rowspan="1">Older (&#8805;65 yr) adult inpatients with dementia from a single-centre geronto-psychiatric hospital</td><td colspan="1" rowspan="1">LTC count</td><td colspan="1" rowspan="1">Opioids</td></tr><tr><td colspan="1" rowspan="1">Cano-Escalera and colleagues, 2023<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref></td><td colspan="1" rowspan="1">Spain</td><td colspan="1" rowspan="1">Prospective cohort</td><td colspan="1" rowspan="1">Sep 2017&#8211;Jan 2021</td><td colspan="1" rowspan="1">Secondary</td><td colspan="1" rowspan="1">Hospital adult inpatients (internal medicine or neurology)</td><td colspan="1" rowspan="1">CCI</td><td colspan="1" rowspan="1">Opioids</td></tr><tr><td colspan="1" rowspan="1">Kim and Suh, 2023<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref></td><td colspan="1" rowspan="1">South Korea</td><td colspan="1" rowspan="1">Retrospective cohort</td><td colspan="1" rowspan="1">Jan 2010&#8211;Dec 2015</td><td colspan="1" rowspan="1">Primary and secondary</td><td colspan="1" rowspan="1">Adult outpatients using opioids for chronic non-cancer pain</td><td colspan="1" rowspan="1">CCI</td><td colspan="1" rowspan="1">Opioids</td></tr><tr><td colspan="1" rowspan="1">Weiner and colleagues, 2022<xref rid="bib72" ref-type="bibr"><sup>72</sup></xref></td><td colspan="1" rowspan="1">USA</td><td colspan="1" rowspan="1">Retrospective cohort</td><td colspan="1" rowspan="1">Jan 2015&#8211;Dec 2018</td><td colspan="1" rowspan="1">Primary and secondary (population based)</td><td colspan="1" rowspan="1">Opioid-naive community dwelling adults prescribed index opioid in 2015</td><td colspan="1" rowspan="1">LTC count</td><td colspan="1" rowspan="1">Opioids</td></tr><tr><td colspan="1" rowspan="1">Thakarar and colleagues, 2021<xref rid="bib70" ref-type="bibr"><sup>70</sup></xref></td><td colspan="1" rowspan="1">USA</td><td colspan="1" rowspan="1">Cross-sectional</td><td colspan="1" rowspan="1">N/R</td><td colspan="1" rowspan="1">Secondary</td><td colspan="1" rowspan="1">People with HIV on chronic opioid therapy</td><td colspan="1" rowspan="1">CCI</td><td colspan="1" rowspan="1">Opioids</td></tr><tr><td colspan="1" rowspan="1">H&#228;user and colleagues, 2020<xref rid="bib63" ref-type="bibr"><sup>63</sup></xref></td><td colspan="1" rowspan="1">Germany</td><td colspan="1" rowspan="1">Retrospective cohort</td><td colspan="1" rowspan="1">Jan 2012&#8211;Dec 2017</td><td colspan="1" rowspan="1">Primary and secondary</td><td colspan="1" rowspan="1">Adults outpatients with chronic non-cancer pain</td><td colspan="1" rowspan="1">CCI [Quan update]</td><td colspan="1" rowspan="1">Opioids</td></tr><tr><td colspan="1" rowspan="1">Lobo and colleagues, 2020<xref rid="bib67" ref-type="bibr"><sup>67</sup></xref></td><td colspan="1" rowspan="1">USA</td><td colspan="1" rowspan="1">Retrospective cohort</td><td colspan="1" rowspan="1">Jan 2007&#8211;Dec 2015</td><td colspan="1" rowspan="1">Primary and secondary</td><td colspan="1" rowspan="1">Adults patients enrolled in Medicaid prescribed an opioid</td><td colspan="1" rowspan="1">ECI</td><td colspan="1" rowspan="1">Opioids</td></tr><tr><td colspan="1" rowspan="1">Glanz and colleagues, 2019<xref rid="bib62" ref-type="bibr"><sup>62</sup></xref></td><td colspan="1" rowspan="1">USA</td><td colspan="1" rowspan="1">Case control</td><td colspan="1" rowspan="1">Jan 2006&#8211;June 2018</td><td colspan="1" rowspan="1">Primary and secondary</td><td colspan="1" rowspan="1">Adult outpatients</td><td colspan="1" rowspan="1">CCI [Quan-Deyo]</td><td colspan="1" rowspan="1">Opioids</td></tr><tr><td colspan="1" rowspan="1">Shafi and colleagues, 2018<xref rid="bib69" ref-type="bibr"><sup>69</sup></xref></td><td colspan="1" rowspan="1">USA</td><td colspan="1" rowspan="1">Retrospective cohort</td><td colspan="1" rowspan="1">Jan 2013&#8211;Sep 2015</td><td colspan="1" rowspan="1">Secondary</td><td colspan="1" rowspan="1">Inpatient adults who underwent surgical or endoscopic procedures</td><td colspan="1" rowspan="1">CCI</td><td colspan="1" rowspan="1">Opioids</td></tr><tr><td colspan="1" rowspan="1">Zhang and colleagues, 2018<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref></td><td colspan="1" rowspan="1">USA</td><td colspan="1" rowspan="1">Retrospective cohort</td><td colspan="1" rowspan="1">Jan 2011&#8211;March 2015</td><td colspan="1" rowspan="1">Secondary</td><td colspan="1" rowspan="1">Hospital inpatient adults with sepsis</td><td colspan="1" rowspan="1">CCI</td><td colspan="1" rowspan="1">Opioids</td></tr><tr><td colspan="1" rowspan="1">Maiti and colleagues, 2018<xref rid="bib68" ref-type="bibr"><sup>68</sup></xref></td><td colspan="1" rowspan="1">USA</td><td colspan="1" rowspan="1">Retrospective cohort</td><td colspan="1" rowspan="1">Sep 2014&#8211;Oct 2015</td><td colspan="1" rowspan="1">Secondary</td><td colspan="1" rowspan="1">Older (&gt;65 yr) adult inpatients in internal medical wards</td><td colspan="1" rowspan="1">CCI</td><td colspan="1" rowspan="1">Opioids</td></tr><tr><td colspan="1" rowspan="1">Lee and colleagues, 2016<xref rid="bib66" ref-type="bibr"><sup>66</sup></xref></td><td colspan="1" rowspan="1">Taiwan</td><td colspan="1" rowspan="1">Retrospective cohort</td><td colspan="1" rowspan="1">2000&#8211;2011</td><td colspan="1" rowspan="1">Secondary</td><td colspan="1" rowspan="1">Female adult hospital inpatients with breast cancer</td><td colspan="1" rowspan="1">CCI</td><td colspan="1" rowspan="1">Opioids</td></tr><tr><td colspan="1" rowspan="1">Thorell and colleagues, 2014<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref></td><td colspan="1" rowspan="1">Sweden</td><td colspan="1" rowspan="1">Retrospective cohort</td><td colspan="1" rowspan="1">2006&#8211;2007</td><td colspan="1" rowspan="1">Primary and secondary (population based)</td><td colspan="1" rowspan="1">Total population of older adults (&#8805;75 yr) in &#214;sterg&#246;tland County</td><td colspan="1" rowspan="1">ACG case-mix system</td><td colspan="1" rowspan="1">Opioids</td></tr><tr><td colspan="1" rowspan="1">Kessler and colleagues, 2013<xref rid="bib64" ref-type="bibr"><sup>64</sup></xref></td><td colspan="1" rowspan="1">USA</td><td colspan="1" rowspan="1">Retrospective cohort</td><td colspan="1" rowspan="1">Jan 2009&#8211;Dec 2010</td><td colspan="1" rowspan="1">Secondary</td><td colspan="1" rowspan="1">Postoperative hospital inpatient adults</td><td colspan="1" rowspan="1">CCI [Dartmouth-Manitoba]</td><td colspan="1" rowspan="1">Opioids</td></tr><tr><td colspan="1" rowspan="1">Gianni and colleagues, 2011<xref rid="bib61" ref-type="bibr"><sup>61</sup></xref></td><td colspan="1" rowspan="1">Italy</td><td colspan="1" rowspan="1">Non-randomised interventional</td><td colspan="1" rowspan="1">N/R</td><td colspan="1" rowspan="1">Secondary</td><td colspan="1" rowspan="1">Ambulatory older (&gt;70 yr) outpatients with chronic non-cancer pain</td><td colspan="1" rowspan="1">Cumulative Illness Rating Scale</td><td colspan="1" rowspan="1">Opioids</td></tr><tr><td colspan="1" rowspan="1">Zemedikun and colleagues, 2022<xref rid="bib74" ref-type="bibr"><sup>74</sup></xref></td><td colspan="1" rowspan="1">UK</td><td colspan="1" rowspan="1">Retrospective cohort</td><td colspan="1" rowspan="1">Jan 2000&#8211;Dec 2019</td><td colspan="1" rowspan="1">Primary</td><td colspan="1" rowspan="1">Primary care adults with OA (matched to those without OA)</td><td colspan="1" rowspan="1">LTC count</td><td colspan="1" rowspan="1">Opioids and NSAIDs<sup>&#8727;</sup></td></tr><tr><td colspan="1" rowspan="1">Bonnesen and colleagues, 2023<xref rid="bib85" ref-type="bibr"><sup>85</sup></xref></td><td colspan="1" rowspan="1">Denmark</td><td colspan="1" rowspan="1">Retrospective cohort</td><td colspan="1" rowspan="1">2012&#8211;Dec 2020</td><td colspan="1" rowspan="1">Primary and secondary (population based)</td><td colspan="1" rowspan="1">Primary and secondary care patients with first time HbA1C &#8805;48 mmol mol<sup>&#8722;1</sup></td><td colspan="1" rowspan="1">rDANCAMI score</td><td colspan="1" rowspan="1">NSAIDs</td></tr><tr><td colspan="1" rowspan="1">Yamanashi and colleagues, 2023<xref rid="bib83" ref-type="bibr"><sup>83</sup></xref></td><td colspan="1" rowspan="1">USA</td><td colspan="1" rowspan="1">Retrospective cohort</td><td colspan="1" rowspan="1">Jan 2016&#8211;March 2020</td><td colspan="1" rowspan="1">Secondary</td><td colspan="1" rowspan="1">Voluntary adult inpatients or ED attenders</td><td colspan="1" rowspan="1">CCI</td><td colspan="1" rowspan="1">NSAIDs</td></tr><tr><td colspan="1" rowspan="1">Hall and colleagues, 2022<xref rid="bib80" ref-type="bibr"><sup>80</sup></xref></td><td colspan="1" rowspan="1">USA</td><td colspan="1" rowspan="1">Retrospective cohort</td><td colspan="1" rowspan="1">Sep 2012&#8211;May 2018</td><td colspan="1" rowspan="1">Secondary</td><td colspan="1" rowspan="1">Older (&#8805;60 yr) surgical trauma inpatients</td><td colspan="1" rowspan="1">LTC count</td><td colspan="1" rowspan="1">NSAIDs</td></tr><tr><td colspan="1" rowspan="1">Glassou and colleagues, 2019<xref rid="bib79" ref-type="bibr"><sup>79</sup></xref></td><td colspan="1" rowspan="1">Denmark</td><td colspan="1" rowspan="1">Prospective cohort</td><td colspan="1" rowspan="1">Jan 2005&#8211;Dec 2016</td><td colspan="1" rowspan="1">Secondary</td><td colspan="1" rowspan="1">Older (&#8805;65 yr) adult inpatients with a surgically treated hip fracture</td><td colspan="1" rowspan="1">CCI</td><td colspan="1" rowspan="1">NSAIDs</td></tr><tr><td colspan="1" rowspan="1">Cho and colleagues, 2018<xref rid="bib77" ref-type="bibr"><sup>77</sup></xref></td><td colspan="1" rowspan="1">South Korea</td><td colspan="1" rowspan="1">Case control</td><td colspan="1" rowspan="1">Jan 2010&#8211;Dec 2013</td><td colspan="1" rowspan="1">Primary and secondary</td><td colspan="1" rowspan="1">South Asian outpatient adults with rheumatoid arthritis</td><td colspan="1" rowspan="1">CCI</td><td colspan="1" rowspan="1">NSAIDs</td></tr><tr><td colspan="1" rowspan="1">Liu and colleagues, 2018<xref rid="bib81" ref-type="bibr"><sup>81</sup></xref></td><td colspan="1" rowspan="1">Canada</td><td colspan="1" rowspan="1">Case control</td><td colspan="1" rowspan="1">July 1991&#8211;March 2015</td><td colspan="1" rowspan="1">Secondary</td><td colspan="1" rowspan="1">Adult inpatients hospitalised with TMA</td><td colspan="1" rowspan="1">ADG score</td><td colspan="1" rowspan="1">NSAIDs</td></tr><tr><td colspan="1" rowspan="1">Gallagher and colleagues, 2012<xref rid="bib78" ref-type="bibr"><sup>78</sup></xref></td><td colspan="1" rowspan="1">USA</td><td colspan="1" rowspan="1">Retrospective cohort</td><td colspan="1" rowspan="1">N/R</td><td colspan="1" rowspan="1">Secondary</td><td colspan="1" rowspan="1">Adult hospital inpatients or outpatients with depression</td><td colspan="1" rowspan="1">CCI [age adjusted]</td><td colspan="1" rowspan="1">NSAIDs</td></tr><tr><td colspan="1" rowspan="1">Humes and colleagues, 2011<xref rid="bib75" ref-type="bibr"><sup>75</sup></xref></td><td colspan="1" rowspan="1">UK</td><td colspan="1" rowspan="1">Case control</td><td colspan="1" rowspan="1">Jan 1990&#8211;Dec 2005</td><td colspan="1" rowspan="1">Primary care</td><td colspan="1" rowspan="1">Patients with diverticular perforation</td><td colspan="1" rowspan="1">CCI</td><td colspan="1" rowspan="1">NSAIDs</td></tr><tr><td colspan="1" rowspan="1">Abraham and colleagues, 2008<xref rid="bib76" ref-type="bibr"><sup>76</sup></xref></td><td colspan="1" rowspan="1">USA</td><td colspan="1" rowspan="1">Retrospective cohort</td><td colspan="1" rowspan="1">Jan 2000&#8211;Dec 2002</td><td colspan="1" rowspan="1">Primary &amp; secondary</td><td colspan="1" rowspan="1">Older adult (&gt;65 yr) veteran outpatients</td><td colspan="1" rowspan="1">CCI [Deyo] and LTC count</td><td colspan="1" rowspan="1">NSAIDs</td></tr><tr><td colspan="1" rowspan="1">Stockl and colleagues, 2005<xref rid="bib82" ref-type="bibr"><sup>82</sup></xref></td><td colspan="1" rowspan="1">USA</td><td colspan="1" rowspan="1">Retrospective cohort</td><td colspan="1" rowspan="1">July 1998&#8211;Aug 2002</td><td colspan="1" rowspan="1">Primary and secondary</td><td colspan="1" rowspan="1">Adult outpatients</td><td colspan="1" rowspan="1">CCI</td><td colspan="1" rowspan="1">NSAIDs</td></tr><tr><td colspan="1" rowspan="1">Park and colleagues, 2022<xref rid="bib84" ref-type="bibr"><sup>84</sup></xref></td><td colspan="1" rowspan="1">USA</td><td colspan="1" rowspan="1">Retrospective cohort</td><td colspan="1" rowspan="1">Jan 2009&#8211;May 2022</td><td colspan="1" rowspan="1">Secondary</td><td colspan="1" rowspan="1">Older (&gt;65 yr) postoperative adult hospital inpatients</td><td colspan="1" rowspan="1">Combined comorbidity index</td><td colspan="1" rowspan="1">Gabapentinoids</td></tr></tbody></table></table-wrap></p></sec><sec id="sec2.3"><title>Multimorbidity measurement</title><p id="p0100">A definition of multimorbidity was provided in one study,<xref rid="bib74" ref-type="bibr"><sup>74</sup></xref> but otherwise, multimorbidity was not defined explicitly in the remaining studies. Multimorbidity was measured using the following indices; the Charlson Comorbidity Index (CCI) or modification (<italic toggle="yes">n</italic>=17),<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref><sup>,</sup><xref rid="bib62" ref-type="bibr">62</xref>, <xref rid="bib63" ref-type="bibr">63</xref>, <xref rid="bib64" ref-type="bibr">64</xref>, <xref rid="bib65" ref-type="bibr">65</xref>, <xref rid="bib66" ref-type="bibr">66</xref><sup>,</sup><xref rid="bib68" ref-type="bibr">68</xref>, <xref rid="bib69" ref-type="bibr">69</xref>, <xref rid="bib70" ref-type="bibr">70</xref><sup>,</sup><xref rid="bib73" ref-type="bibr"><sup>73</sup></xref><sup>,</sup><xref rid="bib75" ref-type="bibr">75</xref>, <xref rid="bib76" ref-type="bibr">76</xref>, <xref rid="bib77" ref-type="bibr">77</xref>, <xref rid="bib78" ref-type="bibr">78</xref>, <xref rid="bib79" ref-type="bibr">79</xref><sup>,</sup><xref rid="bib82" ref-type="bibr"><sup>82</sup></xref><sup>,</sup><xref rid="bib83" ref-type="bibr"><sup>83</sup></xref> LTC count (<italic toggle="yes">n</italic>=4),<xref rid="bib72" ref-type="bibr"><sup>72</sup></xref><sup>,</sup><xref rid="bib74" ref-type="bibr"><sup>74</sup></xref><sup>,</sup><xref rid="bib80" ref-type="bibr"><sup>80</sup></xref><sup>,</sup><xref rid="bib86" ref-type="bibr"><sup>86</sup></xref> Elixhauser comorbidity index (ECI, <italic toggle="yes">n</italic>=1),<xref rid="bib67" ref-type="bibr"><sup>67</sup></xref> combined comorbidity index (<italic toggle="yes">n</italic>=1),<xref rid="bib84" ref-type="bibr"><sup>84</sup></xref> cumulative illness rating scale (<italic toggle="yes">n</italic>=1),<xref rid="bib61" ref-type="bibr"><sup>61</sup></xref> Danish Comorbidity Index for Acute Myocardial Infarction restricted to non-cardiovascular diseases (rDANCAMI) score (<italic toggle="yes">n</italic>=1),<xref rid="bib85" ref-type="bibr"><sup>85</sup></xref> John Hopkins aggregated diagnosis group score (ADG) (<italic toggle="yes">n</italic>=1)<xref rid="bib81" ref-type="bibr"><sup>81</sup></xref> or adjusted clinical group (ACG) case-mix system.<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref> Most studies did not report the number of conditions incorporated in their reported measure of multimorbidity.<xref rid="bib60" ref-type="bibr">60</xref>, <xref rid="bib61" ref-type="bibr">61</xref>, <xref rid="bib62" ref-type="bibr">62</xref><sup>,</sup><xref rid="bib65" ref-type="bibr"><sup>65</sup></xref><sup>,</sup><xref rid="bib67" ref-type="bibr">67</xref>, <xref rid="bib68" ref-type="bibr">68</xref>, <xref rid="bib69" ref-type="bibr">69</xref>, <xref rid="bib70" ref-type="bibr">70</xref>, <xref rid="bib71" ref-type="bibr">71</xref>, <xref rid="bib72" ref-type="bibr">72</xref>, <xref rid="bib73" ref-type="bibr">73</xref><sup>,</sup><xref rid="bib75" ref-type="bibr">75</xref>, <xref rid="bib76" ref-type="bibr">76</xref>, <xref rid="bib77" ref-type="bibr">77</xref>, <xref rid="bib78" ref-type="bibr">78</xref>, <xref rid="bib79" ref-type="bibr">79</xref>, <xref rid="bib80" ref-type="bibr">80</xref>, <xref rid="bib81" ref-type="bibr">81</xref>, <xref rid="bib82" ref-type="bibr">82</xref>, <xref rid="bib83" ref-type="bibr">83</xref>, <xref rid="bib84" ref-type="bibr">84</xref><sup>,</sup><xref rid="bib86" ref-type="bibr"><sup>86</sup></xref></p></sec><sec id="sec2.4"><title>Assessment of heterogeneity</title><p id="p0105">Quantitative assessment of heterogeneity was not possible because of the absence of quantitative synthesis. A formal qualitative assessment of heterogeneity was not judged to be of value based on the marked variation in study methodologies, analgesic exposure(s), adverse outcome(s), measurement and reporting of multimorbidity.</p></sec><sec id="sec2.5"><title>Risk of bias</title><p id="p0110">Risk of bias of observational studies included in the review is summarised in <xref rid="tbl2" ref-type="table">Table&#160;2</xref>. Overall, 10 studies were rated as &#8216;<italic toggle="yes">good</italic>&#8217;, six &#8216;<italic toggle="yes">fair</italic>&#8217;, and 10 &#8216;<italic toggle="yes">poor</italic>&#8217;. Few studies used a new user design with quantification of time-varying cumulative analgesic exposure. Other common sources of bias included measurement and misclassification through an absence of analgesic dosing informationor adequate description, length or completeness of follow-up. Quality assessment of the single interventional study is summarised in <xref rid="appsec1" ref-type="sec">Supplementary material S3</xref>. It was judged to be at serious risk of bias because of the absence of both a comparator group and multivariable adjustment.<table-wrap position="float" id="tbl2" orientation="portrait"><label>Table&#160;2</label><caption><p>Risk of bias of observational studies.</p></caption><alt-text id="alttext0025">Table&#160;2</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Author year</th><th colspan="1" rowspan="1">Selection</th><th colspan="1" rowspan="1">Comparability</th><th colspan="1" rowspan="1">Outcome/exposure</th><th colspan="1" rowspan="1">Overall</th></tr></thead><tbody><tr><td colspan="5" rowspan="1">Cohort studies</td></tr><tr><td colspan="1" rowspan="1">Kim 2023</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">1&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">Fair quality</td></tr><tr><td colspan="1" rowspan="1">Bonnesen 2023</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">Fair quality</td></tr><tr><td colspan="1" rowspan="1">Lee 2016</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">Fair quality</td></tr><tr><td colspan="1" rowspan="1">Lobo 2020</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">Fair quality</td></tr><tr><td colspan="1" rowspan="1">Park 2022</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">Fair quality</td></tr><tr><td colspan="1" rowspan="1">Stockl 2005</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">Fair quality</td></tr><tr><td colspan="1" rowspan="1">Abraham 2008</td><td colspan="1" rowspan="1">3&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">Good quality</td></tr><tr><td colspan="1" rowspan="1">Glassou 2019</td><td colspan="1" rowspan="1">3&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">Good quality</td></tr><tr><td colspan="1" rowspan="1">H&#228;user 2020</td><td colspan="1" rowspan="1">4&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">Good quality</td></tr><tr><td colspan="1" rowspan="1">Shafi 2018</td><td colspan="1" rowspan="1">3&#8727;</td><td colspan="1" rowspan="1">1&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">Good quality</td></tr><tr><td colspan="1" rowspan="1">Weiner 2022</td><td colspan="1" rowspan="1">3&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">Good quality</td></tr><tr><td colspan="1" rowspan="1">Zemedikun 2022</td><td colspan="1" rowspan="1">3&#8727;</td><td colspan="1" rowspan="1">1&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">Good quality</td></tr><tr><td colspan="1" rowspan="1">Zhang 2018</td><td colspan="1" rowspan="1">3&#8727;</td><td colspan="1" rowspan="1">1&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">Good quality</td></tr><tr><td colspan="1" rowspan="1">Cano-Escalera 2023</td><td colspan="1" rowspan="1">1&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">Poor quality</td></tr><tr><td colspan="1" rowspan="1">Gallagher 2012</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">1&#8727;</td><td colspan="1" rowspan="1">1&#8727;</td><td colspan="1" rowspan="1">Poor quality</td></tr><tr><td colspan="1" rowspan="1">Hall 2022</td><td colspan="1" rowspan="1">0&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">0&#8727;</td><td colspan="1" rowspan="1">Poor quality</td></tr><tr><td colspan="1" rowspan="1">Kessler 2013</td><td colspan="1" rowspan="1">1&#8727;</td><td colspan="1" rowspan="1">1&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">Poor quality</td></tr><tr><td colspan="1" rowspan="1">Maiti 2018</td><td colspan="1" rowspan="1">3&#8727;</td><td colspan="1" rowspan="1">0&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">Poor quality</td></tr><tr><td colspan="1" rowspan="1">Thorell 2014</td><td colspan="1" rowspan="1">3&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">1&#8727;</td><td colspan="1" rowspan="1">Poor quality</td></tr><tr><td colspan="1" rowspan="1">Yamanashi 2023</td><td colspan="1" rowspan="1">1&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">1&#8727;</td><td colspan="1" rowspan="1">Poor quality</td></tr><tr><td colspan="5" rowspan="1">Case control studies</td></tr><tr><td colspan="1" rowspan="1">Cho 2018</td><td colspan="1" rowspan="1">4&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">1&#8727;</td><td colspan="1" rowspan="1">Poor quality</td></tr><tr><td colspan="1" rowspan="1">Podesser 2024</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">1&#8727;</td><td colspan="1" rowspan="1">1&#8727;</td><td colspan="1" rowspan="1">Poor quality</td></tr><tr><td colspan="1" rowspan="1">Glanz 2019</td><td colspan="1" rowspan="1">4&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">Good quality</td></tr><tr><td colspan="1" rowspan="1">Humes 2011</td><td colspan="1" rowspan="1">4&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">Good quality</td></tr><tr><td colspan="1" rowspan="1">Liu 2018</td><td colspan="1" rowspan="1">4&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">Good quality</td></tr><tr><td colspan="5" rowspan="1">Cross-sectional studies</td></tr><tr><td colspan="1" rowspan="1">Thakarar 2021</td><td colspan="1" rowspan="1">0&#8727;</td><td colspan="1" rowspan="1">2&#8727;</td><td colspan="1" rowspan="1">1&#8727;</td><td colspan="1" rowspan="1">Poor quality</td></tr></tbody></table></table-wrap></p></sec><sec id="sec2.6"><title>Opioids</title><p id="p0115">Among 16 studies that investigated opioids, 12 reported evidence of harms, while four found no evidence of harm. Characteristics and results of studies reporting adverse opioid-related outcomes are summarised in <xref rid="tbl3" ref-type="table">Table&#160;3</xref>.<table-wrap position="float" id="tbl3" orientation="portrait"><label>Table 3</label><caption><p>Characteristics and results of studies of opioids, <italic toggle="yes">n</italic>=16. ACG, adjusted clinical group; ADE, adverse drug event; ADR, adverse drug reaction; aHR, adjusted hazard ratio; AIDS, acquired immunodeficiency syndrome; <sc>anova</sc>, analysis of variance; ARR, adjusted rate ratio; BZD, benzodiazepine; CCI, Charlson Comorbidity Index; CI, confidence interval; CIRS, cumulative illness rating scale; CHF, congestive heart failure; DM, diabetes mellitus; DVT, deep venous thrombosis; ECI, Elixhauser comorbidity index; ED, emergency department; EHR, electronic health record; HIV, human immunodeficiency virus; HR, hazard ratio; JH, John Hopkins; ICD, International Classification of Diseases; IMRD-UK, IQVIA Medical Research Data UK; IQR, interquartile range; LCA, latent class analysis; LHID-CIP, Longitudinal Health Insurance Database for Catastrophic Illness Patients; LOS, length of stay; LTC, long-term condition; MEQ, morphine equivalent; MM, multimorbidity; MME, morphine milligram equivalent; MNA, Mini Nutritional Assessment; NHIS-NSC, National Health Insurance Service National Sample Cohort; N/R, not reported; OA, osteoarthritis; OD, overdose; ORADE, opioid-related adverse drug event; OR, odds ratio; PPI, proton pump inhibitor; PRN, as required; PSM, propensity score matching; RUB, resource utilisation bands; <sc>sd</sc>, standard deviation; WBC, white blood cell. &#8727;Age in yr presented as mean (SD) unless stated otherwise. <sup>&#8224;</sup>Patients in the same ACG group have the &#8216;same type and degree of multimorbidity&#8217;.</p></caption><alt-text id="alttext0030">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="9" rowspan="1">Studies reporting drug-related harm (secondary care)<hr/></th></tr><tr><th rowspan="2" colspan="1">Reference</th><th rowspan="2" colspan="1">Sample size</th><th colspan="3" rowspan="1">Patient characteristics<hr/></th><th rowspan="2" colspan="1">Analgesic exposure</th><th rowspan="2" colspan="1">Adverse outcome definition and timing</th><th rowspan="2" colspan="1">Analysis</th><th rowspan="2" colspan="1">Main findings</th></tr><tr><th colspan="1" rowspan="1">Measurement of multimorbidity</th><th colspan="1" rowspan="1">Female, <italic toggle="yes">n</italic> (%)</th><th colspan="1" rowspan="1">Age&#8727;</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Shafi and colleagues, 2018<xref rid="bib69" ref-type="bibr"><sup>69</sup></xref></td><td colspan="1" rowspan="1">135&#160;379</td><td colspan="1" rowspan="1">CCI measured upon admission via ICD-9. Number of conditions N/R. Mean (<sc>sd</sc>) CCI sub-populations: ORADE 4.0 (2.9) <italic toggle="yes">vs</italic> non-ORADE 2.2 (2.7).</td><td colspan="1" rowspan="1">91&#160;371 (67.5)</td><td colspan="1" rowspan="1">58.9 (17.4)</td><td colspan="1" rowspan="1">Administrative database. Prevalent user design. No information on dosing.</td><td colspan="1" rowspan="1">ORADE defined as one or more well-known adverse effects of opioids during hospitalisation.</td><td colspan="1" rowspan="1">Unadjusted differences between ORADE and non-ORADE.</td><td colspan="1" rowspan="1"><italic toggle="yes">MM measure higher in ORADE group:</italic> ORADE positive (<italic toggle="yes">n</italic>=4386, 10.6%) mean (<sc>sd</sc>) CCI 4.0 (2.9) <italic toggle="yes">vs</italic> ORADE negative (<italic toggle="yes">n</italic>=120&#160;993) CCI 2.2 (2.7).<break/><italic toggle="yes">MM measure higher with increasing ORADE severity:</italic> CCI mean (<sc>sd</sc>): Severe ORADE: 4.3 (2.8); moderate: 3.8 (2.9); mild: 3.1 (2.8).</td></tr><tr><td colspan="1" rowspan="1">Kessler and colleagues, 2013<xref rid="bib64" ref-type="bibr"><sup>64</sup></xref></td><td colspan="1" rowspan="1">37&#160;031</td><td colspan="1" rowspan="1">CCI [Dartmouth-Manitoba] measured during hospitalisation via ICD-9. 19 conditions in MM measure. Mean (<sc>sd</sc>) CCI study population: 1.15 (1.7) [pre-PSM].</td><td colspan="1" rowspan="1">25&#160;403 (68.6)</td><td colspan="1" rowspan="1">60.4 (18.3)</td><td colspan="1" rowspan="1">Charge codes from administrative data of financial transactions. Prevalent user design. No information on dosing.</td><td colspan="1" rowspan="1">ORADE defined as per large list in <xref rid="tbl2" ref-type="table">Table 2</xref> during hospitalisation.</td><td colspan="1" rowspan="1">Multiple logistic regression with PSM 1:1 age, race-ethnicity, sex, pre-surgery opioid use, and comorbidities. Adjusted for age &#8805;65 yr, sex, race-ethnicity, obesity, degenerative joint disease, and opioid use before surgery.</td><td colspan="1" rowspan="1"><italic toggle="yes">MM measure higher in ORADE group</italic>: ORADE (<italic toggle="yes">n</italic>=4955, 13.6%) mean (<sc>sd</sc>) CCI 1.87 (2.1) <italic toggle="yes">vs</italic> no ORADE (<italic toggle="yes">n</italic>=31&#160;574) CCI 1.04 (1.6) [pre-PSM].<break/><italic toggle="yes">Increasing MM measure associated with ORADEs among opioid exposed adults:</italic> Risk of ORADEs by CCI (per one point increase) OR 1.18 (95% CI 1.16&#8211;1.19, <italic toggle="yes">P</italic>&lt;0.0001).</td></tr><tr><td colspan="1" rowspan="1">Zhang and colleagues, 2018<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref></td><td colspan="1" rowspan="1">5994</td><td colspan="1" rowspan="1">CCI. Timing and number of conditions N/R. Mean (<sc>sd</sc>) CCI sub-population, opioid exposed group: 4.67 (5.71).</td><td colspan="1" rowspan="1">3,006 (50.1)</td><td colspan="1" rowspan="1">60.9 (N/R)</td><td colspan="1" rowspan="1">Medication administration chart during hospitalisation. New user design. No information on dosing.</td><td colspan="1" rowspan="1">All-cause mortality at 28 days.</td><td colspan="1" rowspan="1">Cox proportional hazard analysis (1) unadjusted; (2) age, gender, BMI, WBC count.</td><td colspan="1" rowspan="1"><italic toggle="yes">Opioids use vs non-use associated with mortality in MM adults:</italic> Crude mortality: opioid 10.35% <italic toggle="yes">vs</italic> non-opioid 2.4%. Unadjusted HR 5.951 (4.218&#8211;8.396) &lt;0.0001; demographic model (2) aHR 7.321 (5.178&#8211;10.349) &lt;0.0001.</td></tr><tr><td colspan="1" rowspan="1">Maiti and colleagues, 2018<xref rid="bib68" ref-type="bibr"><sup>68</sup></xref></td><td colspan="1" rowspan="1">9245</td><td colspan="1" rowspan="1">CCI. Timing and number of conditions N/R. Mean (<sc>sd</sc>) CCI study population: 7.1 (2.5).</td><td colspan="1" rowspan="1">5099 (55.2)</td><td colspan="1" rowspan="1">80.3 (8.8)</td><td colspan="1" rowspan="1">EHR prescribing data with morphine milligrams equivalent per patient. Non-, prior and new opioid users recorded.</td><td colspan="1" rowspan="1">Hospital length of stay and 30-day hospital re-admission.</td><td colspan="1" rowspan="1">Descriptive/<sc>anova</sc> without adjustment.</td><td colspan="1" rowspan="1"><italic toggle="yes">Current and former opioid users have longer LOS and 30-day readmissions than non-users in MM adults:</italic> new opiates (<italic toggle="yes">n</italic>=1915): MEQ per patient, mean (<sc>sd</sc>) 296.9 (1779.1). LOS mean 7.7 (0.2) <italic toggle="yes">P</italic>&lt;0.001. 30-Day readmissions 426 (22.3%). Prior opiates (<italic toggle="yes">n</italic>=400): MEQ per patient, mean (<sc>sd</sc>) 421.9 (1948.3). LOS mean 6.8 (<sc>sd</sc> 0.3). 30-day readmissions 100 (25.0%). No opiates (<italic toggle="yes">n</italic>=6930). LOS mean 5.2 (<sc>sd</sc> 0.1). 30-day readmissions 1361 (19.6%). Participants never exposed to opiates had a shorter LOS than those receiving short- and long-acting opiates (5.2, 7.3, 8.6 days; <italic toggle="yes">P</italic>&lt;0.001) and less likely to be readmitted within 30-days (19.6%, 27.7%, 28.9%; <italic toggle="yes">P</italic>&lt;0.001).</td></tr><tr><td colspan="1" rowspan="1">Gianni and colleagues, 2011<xref rid="bib61" ref-type="bibr"><sup>61</sup></xref></td><td colspan="1" rowspan="1">93</td><td colspan="1" rowspan="1">CIRS measured at baseline. Number of conditions N/R. Mean CIRS of study population 3.4 (i.e. severe comorbidities in three organ categories) with mean index of severity 1.8 (i.e. low grade).</td><td colspan="1" rowspan="1">66 (71)</td><td colspan="1" rowspan="1">79.7 (7.1)</td><td colspan="1" rowspan="1">Primary data collection at study visits. Buprenorphine transdermal delivery system (TDS) started using a dose calculated based on equivalent analgesic dose ratios. New user design.</td><td colspan="1" rowspan="1">ADE categorised as slight <italic toggle="yes">vs</italic> moderate <italic toggle="yes">vs</italic> severe (unclear how defined), cessation of treatment and study withdrawal because of side-effects. Nausea, constipation, sleepiness, rash measured up to 90 days.</td><td colspan="1" rowspan="1">Descriptive/ANOVA without adjustment.</td><td colspan="1" rowspan="1"><italic toggle="yes">Opioids associated with ADEs in MM adults</italic>: n=44 (47.3%) reported ADEs; <italic toggle="yes">n</italic>=39 (89%) slight or moderate clinical intensity and <italic toggle="yes">n</italic>=5 (11%) severe. <italic toggle="yes">n</italic>=35 (37%) of patients stopped treatment prematurely; <italic toggle="yes">n</italic>=12 (12.9%) withdrew because of side-effects. The systemic effects most frequently noted: Nausea <italic toggle="yes">n</italic>=7 (15.7%), constipation <italic toggle="yes">n</italic>=7 (15.7%), sleepiness <italic toggle="yes">n</italic>=6 (14.2%), rash <italic toggle="yes">n</italic>=5 (11.2%).</td></tr><tr><td colspan="1" rowspan="1">Thakarar and colleagues 2021<xref rid="bib70" ref-type="bibr"><sup>70</sup></xref></td><td colspan="1" rowspan="1">153</td><td colspan="1" rowspan="1">CCI measured at baseline. Number of conditions N/R. Mean/median CCI N/R.</td><td colspan="1" rowspan="1">54 (35)</td><td colspan="1" rowspan="1">54 median (IQR 49&#8211;59)</td><td colspan="1" rowspan="1">Prescription fill data. MME measured at baseline. Prevalent user design.</td><td colspan="1" rowspan="1">ED attendance at 1 yr.</td><td colspan="1" rowspan="1">Multivariate logistic regression adjusted for age, gender, years on opioids, high-dose opioids, co-prescribing of BZD, lack of opioid treatment agreement, hepatitis C, depression, prior ED visits, HIV-1 RNA &lt;200 copies ml<sup>&#8722;1</sup>.</td><td colspan="1" rowspan="1"><italic toggle="yes">Increasing MM measure associated with ED attendance among opioid exposed adults:</italic> CCI (per one point increase) OR 1.47 (95% 1.17&#8211;1.85) <italic toggle="yes">P</italic> 0.001.</td></tr><tr><td colspan="9" rowspan="1"><bold><italic toggle="yes">Studies reporting drug-related harm (primary and secondary care)</italic></bold></td></tr><tr><td colspan="1" rowspan="1">Weiner and colleagues, 2022<xref rid="bib72" ref-type="bibr"><sup>72</sup></xref></td><td colspan="1" rowspan="1">236&#160;921</td><td colspan="1" rowspan="1">LTC count based on Elixhauser comorbid conditions measured 2 yr before index prescription using ICD-9 and ICD-10. Number of conditions N/R. Compared 1&#8211;2 <italic toggle="yes">vs</italic> 0 and &#8805;3 <italic toggle="yes">vs</italic> 0 LTCs.</td><td colspan="1" rowspan="1">133&#160;860 (56.5)</td><td colspan="1" rowspan="1">N/R (age category only)</td><td colspan="1" rowspan="1">Prescription fill data from linked administrative claims and public health datasets. Monthly time-varying MME sum and number of opioid fills calculated cumulatively over 6 months. New user design.</td><td colspan="1" rowspan="1">Opioid overdose occurring anytime during follow-up (max 4 yr).</td><td colspan="1" rowspan="1">Cox proportional hazard analysis adjusted for index prescription, long-acting formulation, number of benzodiazepine prescriptions, opioid and benzodiazepine overlap, sum of MME, prescription from &#8805;3 prescribers or pharmacies.</td><td colspan="1" rowspan="1"><italic toggle="yes">Opioid overdose increases when stratified by MM measure:</italic> LTC count, <italic toggle="yes">n</italic> (%): 0: 130&#160;093 (54.9%). OD per 100&#160;000 person yr 73.2 (95% CI 64.1&#8211;83.6). LTC 1&#8211;2: 84&#160;018 (35.5%). OD per 100&#160;000 person yr 138.2 (95% CI 122.9&#8211;155.4). LTC 3+: 22&#160;810 (9.6%). OD per 100&#160;000 person yr 321.9 (95% CI 276.8&#8211;374.3)<break/><italic toggle="yes">MM measure associated with opioid overdose in opioid exposed adults:</italic> HR by LTC count: 0: Reference; 1&#8211;2: 1.32 (95% CI 1.08&#8211;1.62) <italic toggle="yes">P</italic> 0.01; &#8805;3: 1.90 (95% CI 1.42&#8211;2.53) <italic toggle="yes">P</italic>&lt;0.001.</td></tr><tr><td colspan="1" rowspan="1">Thorell and colleagues, 2014<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref></td><td colspan="1" rowspan="1">38&#160;407</td><td colspan="1" rowspan="1">JH ACG case-mix grouped by RUBs.<sup>&#8224;</sup> measured from 2006. Number of conditions N/R. Compared subgroups with (RUBs 3&#8211;5) and without (RUBs 0&#8211;2) MM.</td><td colspan="1" rowspan="1">23&#160;428 (61%)</td><td colspan="1" rowspan="1">N/R (age category only)</td><td colspan="1" rowspan="1">Administrative healthcare data. Prevalent user design. No information on dosing.</td><td colspan="1" rowspan="1">Hip fracture occurring any time up to 1 yr.</td><td colspan="1" rowspan="1">Multiple logistic regression: Model A (unadjusted), B (age), C (age and gender) to D (age, gender and MM level).</td><td colspan="1" rowspan="1"><italic toggle="yes">Opioids associated with hip fracture in a subgroup of adults with MM compared with those without MM:</italic> opioids RUBs 0&#8211;2: OR 1.45 (0.99&#8211;2.11) <italic toggle="yes">P</italic>&gt;0.05 <italic toggle="yes">vs</italic> RUBs 3&#8211;5: OR 1.71 (1.44&#8211;2.03) <italic toggle="yes">P</italic>&lt;0.05 [model C].</td></tr><tr><td colspan="1" rowspan="1">Kim and Suh, 2023<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref></td><td colspan="1" rowspan="1">22&#160;524</td><td colspan="1" rowspan="1">CCI. Measured 1 yr before index. Number of conditions N/R. Mean (<sc>sd</sc>) CCI study population 2.0 (<sc>sd</sc> 1.8). Cohort stratified by CCI 0: 20.8%; 1: 26.0%; 2: 20.9%; &#8805;3: 32.3%.</td><td colspan="1" rowspan="1">14&#160;641 (65)</td><td colspan="1" rowspan="1">64 (13)</td><td colspan="1" rowspan="1">Prescription fill data based on NHIS-NSC database. Daily dose of opioids prescribed on index date used to calculate MME. Prevalent user design.</td><td colspan="1" rowspan="1">Opioid abuse defined as shopping or prescription overlap anytime during follow-up (max 6 yr).</td><td colspan="1" rowspan="1">Cox proportional hazard analysis adjusted for age, sex, type of health insurance, history of alcohol abuse, daily dose of opioids prescribed on the index date, a history of opioid abuse categorised as 0, 1&#8211;2, and &#8805;3 of previous abuse events.</td><td colspan="1" rowspan="1"><italic toggle="yes">MM measure associated with opioid abuse among opioid exposed adults</italic>: Prescription opioid abuse by baseline characteristics CCI (per one point increase) 1.054 (95% CI 1.044&#8211;1.065) <italic toggle="yes">P</italic>&lt;0.0001.</td></tr><tr><td colspan="1" rowspan="1">Glanz and colleagues, 2019<xref rid="bib62" ref-type="bibr"><sup>62</sup></xref></td><td colspan="1" rowspan="1">14&#160;898</td><td colspan="1" rowspan="1">CCI [Quan-Deyo modified]. Timing of MM assessment N/R. Number of conditions N/R. Mean (<sc>sd</sc>) CCI study sub-populations cases 2.2 (2.3) <italic toggle="yes">vs</italic> controls 1.4 (1.8).</td><td colspan="1" rowspan="1">8,983 (60.3)</td><td colspan="1" rowspan="1">N/R (age category only)</td><td colspan="1" rowspan="1">Pharmacy claims data using national drug codes. MME calculated for every month of follow-up. Prevalent user design.</td><td colspan="1" rowspan="1">Opioid overdose anytime during follow-up (max 6 yr).</td><td colspan="1" rowspan="1">Multivariate logistic regression. Each case patient with overdose was matched with 20 controls adjusted for opioid dose in the 3 months before index, age, sex, receipt of extended-release, long-acting, or both opioid, mental health disorder, drug or alcohol use disorder, benzodiazepine dispensings, tobacco use or use disorder and race/ethnicity.</td><td colspan="1" rowspan="1"><italic toggle="yes">MM measure associated with opioid overdose among opioid exposed adults</italic>: Modified CCI (per one point increase): Unadjusted OR 1.21 (95% CI 1.14&#8211;1.28); adjusted OR 1.25 (95% CI 1.16&#8211;1.35). Adjusted OR for opioid overdose for those that had sustained opioid discontinuation (i.e. 3-month cessation) modified CCI 1.26 (95% CI 1.17&#8211;1.36).</td></tr><tr><td colspan="1" rowspan="1">H&#228;user and colleagues, 2020<xref rid="bib63" ref-type="bibr"><sup>63</sup></xref></td><td colspan="1" rowspan="1">6464</td><td colspan="1" rowspan="1">CCI [Quan update] measured at baseline. 14 conditions to establish. Mean/median CCI N/R.</td><td colspan="1" rowspan="1">3620 (56)</td><td colspan="1" rowspan="1">66.3 (16.6)</td><td colspan="1" rowspan="1">Prescription fill data from administrative database. Opioid dosage from MEQ values (time-varying), with annual recalculations during follow-up. New user design.</td><td colspan="1" rowspan="1">All-cause mortality anytime during follow-up (max 60 months).</td><td colspan="1" rowspan="1">PSM and cox proportional hazard models adjusted for age, gender, quarter of index treatment, estimated propensity score, study opioid cohort, and treatment duration.</td><td colspan="1" rowspan="1"><italic toggle="yes">MM measure associated with mortality among adults prescribed opioids</italic>: Subgroup with &lt;100 MEQ day<sup>&#8722;</sup><sup>1</sup> (<italic toggle="yes">N</italic>=2943): CCI (per one point increase): HR 1.19 (1.16&#8211;1.22) <italic toggle="yes">P</italic>&lt;0.0001. Subgroup with &gt;100 MEQ day<sup>&#8722;</sup><sup>1</sup> (<italic toggle="yes">N</italic>=189): CCI 1.19 (1.16&#8211;1.23) <italic toggle="yes">P</italic>&lt;0.0001.</td></tr><tr><td colspan="9" rowspan="1"><bold><italic toggle="yes">Studies reporting drug-related harm (primary care)</italic></bold></td></tr><tr><td colspan="1" rowspan="1">Zemedikun and colleagues, 2022<xref rid="bib74" ref-type="bibr"><sup>74</sup></xref></td><td colspan="1" rowspan="1">661&#160;499</td><td colspan="1" rowspan="1">Measured by LTC count any time before diagnosis of OA based on 30 diseases. LTC median (IQR) study sub-populations OA group LTC 2 (1&#8211;4) <italic toggle="yes">vs</italic> non-OA group LTC 1 (0&#8211;3).</td><td colspan="1" rowspan="1">396&#160;802 (60.0)</td><td colspan="1" rowspan="1">62.8 (12.4)</td><td colspan="1" rowspan="1">Prescription data from IMRD-UK EHR database. Prevalent user design. No information on dosing.</td><td colspan="1" rowspan="1">All-cause mortality anytime during follow-up post lag period of 1 yr from index date (maximum 9 yr).</td><td colspan="1" rowspan="1">Cox proportional hazard analysis with LCA matched 1:1 (based on age, sex, and general practice) adjusted for comorbidity phenotypes, age, sex, BMI categories, deprivation quintiles, smoking status, and ethnicity.</td><td colspan="1" rowspan="1"><italic toggle="yes">Opioids associated mortality across all groups, but with greater strength among MM patients</italic>: Cases (i.e. MM): no opioid (reference); weak opioids aHR 1.18 (95% CI 1.15&#8211;1.21); strong opioids aHR 1.80 (95% CI 1.69&#8211;1.92). Controls (i.e. non-MM): no opioid (reference); weak opioids 1.34 (95% CI 1.29&#8211;1.39); strong opioids 1.68 (95% CI 1.50&#8211;1.89).</td></tr><tr><td colspan="9" rowspan="1"><bold><italic toggle="yes">Studies not reporting drug-related harm (any setting)</italic></bold></td></tr><tr><td colspan="1" rowspan="1">Lobo and colleagues, 2019<xref rid="bib67" ref-type="bibr"><sup>67</sup></xref></td><td colspan="1" rowspan="1">432&#160;110</td><td colspan="1" rowspan="1">ECI measured 6 months before index opioid. Number of conditions N/R for ECI which was 'modified by removing the conditions included as covariates'. Mean/median ECI N/R.</td><td colspan="1" rowspan="1">291&#160;674 (67.5)</td><td colspan="1" rowspan="1">30.7 (11.1)</td><td colspan="1" rowspan="1">Administrative database. New user design. Dose captured.</td><td colspan="1" rowspan="1">Opioid use disorder (ICD-9/10); opioid overdose; opioid misuse (based on number of unique prescribers and pharmacies) anytime during study period (maximum 9 yr).</td><td colspan="1" rowspan="1">Multivariate logistic regression with adjustment for age, race, urban/rural living area, enrolment characteristics (eligibility category, managed care/fee-for-service), baseline comorbid conditions (alcohol abuse/dependence, non-opioid drug abuse/dependence, adjustment mood or anxiety disorders, back or neck pain, arthritis/joint pain, headache/migraine, HIV/AIDS), baseline use of benzodiazepines, neuromuscular blocking agents, and ED visits.</td><td colspan="1" rowspan="1"><italic toggle="yes">Impact of MM measure on drug-related harms among opioid exposed adults:</italic> Opioid use disorder: ARR by index prescriber: ECI 0.87 [95% CI 0.85&#8211;0.88] <italic toggle="yes">P</italic>&lt;0.0001. ARR by dominant prescriber: ECI 0.87 [95% CI 0.86&#8211;0.89] <italic toggle="yes">P</italic>&lt;0.0001. Overdose: ARR by index prescriber: ECI 0.97 [95% CI 0.92&#8211;1.02] <italic toggle="yes">P</italic> 0.26. ARR by dominant prescriber: ECI 0.98 [95% CI 0.93&#8211;1.03] <italic toggle="yes">P</italic> 0.360. Opioid misuse: ARR by index prescriber ECI 0.97 [95% CI 0.96&#8211;0.99] <italic toggle="yes">P</italic> 0.004. ARR by dominant prescriber ECI 0.97 [95% CI 0.95&#8211;0.98] <italic toggle="yes">P</italic>&lt;0.0001.</td></tr><tr><td colspan="1" rowspan="1">Lee and colleagues, 2016<xref rid="bib66" ref-type="bibr"><sup>66</sup></xref></td><td colspan="1" rowspan="1">73&#160;917</td><td colspan="1" rowspan="1">CCI measured at baseline. 12 Conditions to calculate CCI. Study population CCI 0: 91.9%, 1&#8211;2: 6.79%, &#8805;3: 1.28%. Study sub-populations: morphine group CCI 0: 90.2%, 1&#8211;2: 8.21%, &#8805;3: 1.56%; no morphine group CCI 0: 92.5%, 1&#8211;2: 6.32%, &#8805;3: 1.18%.</td><td colspan="1" rowspan="1">73,917 (100)</td><td colspan="1" rowspan="1">52.3 (11.9)</td><td colspan="1" rowspan="1">Insurance claims data from LHID-CIP national administrative database to dichotomise users <italic toggle="yes">vs</italic> non-users of morphine. No information on dosing. New user design.</td><td colspan="1" rowspan="1">Atrial fibrillation anytime during follow-up (maximum 10 yr).</td><td colspan="1" rowspan="1">Cox proportional hazard analysis adjusted for age, hypertension, hyperlipidaemia, hyperthyroidism, bisphosphonate use and tamoxifen use.</td><td colspan="1" rowspan="1"><italic toggle="yes">Association between morphine use and atrial fibrillation stratified by MM measure:</italic> in morphine users <italic toggle="yes">vs</italic> non-users, HR stratified by CCI 0: 4.60 (95% CI 3.62&#8211;5.84) <italic toggle="yes">P</italic>&lt;0.001, 1&#8211;2: 4.39 (95% CI 2.79&#8211;6.90) <italic toggle="yes">P</italic>&lt;0.001, &#8805;3: 2.50 (95% CI 1.09&#8211;5.73) <italic toggle="yes">P</italic>&lt;0.05.</td></tr><tr><td colspan="1" rowspan="1">Podesser and colleagues, 2024<xref rid="bib86" ref-type="bibr"><sup>86</sup></xref></td><td colspan="1" rowspan="1">74</td><td colspan="1" rowspan="1">LTC count. Unclear when measured. Number of conditions N/R. LTC study population 7.24 (3.6). LTC count cases 7.4 (3.9). LTC controls 7.0 (3.2)</td><td colspan="1" rowspan="1">28 (37.8)</td><td colspan="1" rowspan="1">82.6 (5.8)</td><td colspan="1" rowspan="1">Medical administration record to determine regular <italic toggle="yes">vs</italic> PRN use of hydromorphone or fentanyl. Prevalent user design. No information on dosing.</td><td colspan="1" rowspan="1">Falls during inpatient hospitalisation excluding those within 48 h of admission.</td><td colspan="1" rowspan="1">Binomial logistic regression analyses through matched case control study matched for sex, age, length of stay, and severity of illness.</td><td colspan="1" rowspan="1"><italic toggle="yes">Opioids were not associated with falls in adults with MM:</italic> 0&#8211;24 h before fall: opioid intake (0&#8211;1) OR 2.24 (95% CI 0.33&#8211;15.18) <italic toggle="yes">P</italic> 0.410. 24&#8211;48 h before fall: opioid intake (0&#8211;1) OR 7.44 (0.70&#8211;78.65) <italic toggle="yes">P</italic> 0.095.</td></tr><tr><td colspan="1" rowspan="1">Cano-Escalera and colleagues, 2023<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref></td><td colspan="1" rowspan="1">714</td><td colspan="1" rowspan="1">CCI. Timing and number of conditions N/R. Study population CCI mean (<sc>sd</sc>) 6.39 (2)</td><td colspan="1" rowspan="1">346 (48.5)</td><td colspan="1" rowspan="1">84.37 (6.76)</td><td colspan="1" rowspan="1">EHR. Prevalent user design. No information on dosing.</td><td colspan="1" rowspan="1">All-cause mortality up to 2 yr.</td><td colspan="1" rowspan="1">Cox proportional hazard analysis adjusted for age, sex, weight, own-home, Barthel, Pfeiffer, MNA weight loss 3 months, MNA mobility, MNA acute disease 3 months, vision loss, constipation, falls, CHF, DVT, cerebrovascular disease, DM, thyroid disease, drug oligopharmacy, PPIs, zolpidem, antidiabetics, and diuretics.</td><td colspan="1" rowspan="1"><italic toggle="yes">Opioids associated with a reduction in mortality in sub-population of MM adults:</italic> pre-frail sub-population only: opiates HR 0.000069 [95% CI 0.00000035&#8211;0.013, <italic toggle="yes">P</italic>&lt;0.001]</td></tr></tbody></table></table-wrap></p><sec id="sec2.6.1"><title>Evidence of drug-related harm (n=12)</title><sec id="sec2.6.1.1"><title>Secondary care settings (n=6)</title><p id="p0120">Six studies reported opioid-related harms in secondary care settings including opioid-related adverse drugs events (ORADEs), hospital length of stay, 30-day re-hospitalisation, emergency department (ED) attendance and mortality.<xref rid="bib61" ref-type="bibr"><sup>61</sup></xref><sup>,</sup><xref rid="bib64" ref-type="bibr"><sup>64</sup></xref><sup>,</sup><xref rid="bib68" ref-type="bibr">68</xref>, <xref rid="bib69" ref-type="bibr">69</xref>, <xref rid="bib70" ref-type="bibr">70</xref><sup>,</sup><xref rid="bib73" ref-type="bibr"><sup>73</sup></xref> Two studies reported a greater prevalence of multimorbidity (i.e. a higher mean CCI) among adults who experienced postoperative ORADEs.<xref rid="bib64" ref-type="bibr"><sup>64</sup></xref><sup>,</sup><xref rid="bib69" ref-type="bibr"><sup>69</sup></xref> CCI was reported to have a dose&#8211;response relationship with the severity of ORADEs<xref rid="bib69" ref-type="bibr"><sup>69</sup></xref> and a modest predictive effect of ORADEs in postoperative adults.<xref rid="bib64" ref-type="bibr"><sup>64</sup></xref> Two studies in medical inpatient settings reported adverse outcomes associated with opioid use in multimorbid populations of adults.<xref rid="bib68" ref-type="bibr"><sup>68</sup></xref><sup>,</sup><xref rid="bib73" ref-type="bibr"><sup>73</sup></xref> Opioid exposure was associated with a seven-fold increase in mortality compared with non-use among patients with sepsis after adjustment for demographic, but not clinical factors.<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref> Among older adults (&gt;65 yr), current and former opioid users had a longer hospital length of stay and an increase in 30-day readmissions compared with non-users on descriptive analyses.<xref rid="bib68" ref-type="bibr"><sup>68</sup></xref> Two studies were conducted in outpatients.<xref rid="bib61" ref-type="bibr"><sup>61</sup></xref><sup>,</sup><xref rid="bib70" ref-type="bibr"><sup>70</sup></xref> In a small trial of buprenorphine for a multimorbid population of older adults with chronic non-cancer pain, nearly half of patients reported adverse events including nausea, constipation, sleepiness, and rash. The findings were descriptive and based on a select cohort of volunteers.<xref rid="bib61" ref-type="bibr"><sup>61</sup></xref> Finally, CCI was associated with ED attendance among patients with human immunodeficiency virus (HIV) treated with chronic opioid therapy.<xref rid="bib70" ref-type="bibr"><sup>70</sup></xref></p></sec><sec id="sec2.6.1.2"><title>Primary and secondary care settings (n=5)</title><p id="p0125">Five studies conducted in primary and secondary care reported opioid-related harms (i.e. opioid overdose, hip fracture, opioid abuse, and mortality).<xref rid="bib62" ref-type="bibr"><sup>62</sup></xref><sup>,</sup><xref rid="bib63" ref-type="bibr"><sup>63</sup></xref><sup>,</sup><xref rid="bib65" ref-type="bibr"><sup>65</sup></xref><sup>,</sup><xref rid="bib71" ref-type="bibr"><sup>71</sup></xref><sup>,</sup><xref rid="bib72" ref-type="bibr"><sup>72</sup></xref> Two studies used population-based data to compare subgroups of people with and without multimorbidity, reporting increased risk of adverse outcomes in individuals with multiple LTCs.<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref><sup>,</sup><xref rid="bib72" ref-type="bibr"><sup>72</sup></xref> Multimorbidity (i.e. increasing LTC count) was associated with an increased incidence of opioid overdose after first opioid prescription for pain.<xref rid="bib72" ref-type="bibr"><sup>72</sup></xref> Opioids were associated with an increased risk of hip fracture in a subgroup of adults with multimorbidity (i.e. resource utilisation bands [RUB] level 3&#8211;5), but not those without (i.e. RUB level 0&#8211;2) in a regression analysis adjusted for age and gender. RUB groups are a proxy indicator of multimorbidity based on the John Hopkins ACG case-mix system.<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref> Multimorbidity (i.e. increasing CCI) was associated with a marginal increase in opioid abuse<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref> and modest increase in overdose<xref rid="bib62" ref-type="bibr"><sup>62</sup></xref> and mortality<xref rid="bib63" ref-type="bibr"><sup>63</sup></xref> among adults exposed to long-term opioids for chronic non-cancer pain.<xref rid="bib62" ref-type="bibr"><sup>62</sup></xref><sup>,</sup><xref rid="bib63" ref-type="bibr"><sup>63</sup></xref><sup>,</sup><xref rid="bib65" ref-type="bibr"><sup>65</sup></xref></p></sec><sec id="sec2.6.1.3"><title>Primary care settings (n=1)</title><p id="p0130">One study, conducted using primary care data, assessed the impact of opioids and NSAIDs on mortality in a population of adults with osteoarthritis and multimorbidity compared with matched controls (without multimorbidity). The authors reported an increase in mortality with weak and strong opioids across all groups, but more so for strong opioids in the sub-population of adults with multimorbidity.<xref rid="bib74" ref-type="bibr"><sup>74</sup></xref></p></sec></sec><sec id="sec2.6.2"><title>No evidence of drug-related harm (n=4)</title><p id="p0135">Four studies did not report evidence of adverse opioid-related outcomes (i.e. opioid use disorder, opioid misuse, opioid overdose, atrial fibrillation, falls or mortality) associated with multimorbidity, or, opioid exposure among people with multimorbidity.<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref><sup>,</sup><xref rid="bib66" ref-type="bibr"><sup>66</sup></xref><sup>,</sup><xref rid="bib67" ref-type="bibr"><sup>67</sup></xref><sup>,</sup><xref rid="bib86" ref-type="bibr"><sup>86</sup></xref> One study found a higher disease burden (measured using the ECI) was associated with a relative risk reduction in opioid use disorder and misuse, but not overdose.<xref rid="bib67" ref-type="bibr"><sup>67</sup></xref> One study reported an association between morphine use and atrial fibrillation compared with non-use among female breast cancer patients, with stratification by CCI showing that the observed association was attenuated with increasing multimorbidity.<xref rid="bib66" ref-type="bibr"><sup>66</sup></xref> Two small, single-centre studies assessed the impact of opioid use compared with non-use among populations of older adults with multimorbidity.<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref><sup>,</sup><xref rid="bib86" ref-type="bibr"><sup>86</sup></xref> One reported no association between short-term opioid intake (0&#8211;24 or 24&#8211;48 h) and falls.<xref rid="bib86" ref-type="bibr"><sup>86</sup></xref> The other reported a dramatic relative reduction in mortality associated with opioid use (defined only as use <italic toggle="yes">vs</italic> non-use) in a pre-frail sub-population of adults, however, crude mortality was not reported.<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref></p></sec></sec><sec id="sec2.7"><title>NSAIDs</title><p id="p0140">Among 11 studies that investigated NSAIDs, six reported evidence of harms, while five found no evidence of harm. Characteristics and results of studies reporting adverse NSAID-related outcomes are summarised in <xref rid="tbl4" ref-type="table">Table&#160;4</xref>.<table-wrap position="float" id="tbl4" orientation="portrait"><label>Table 4</label><caption><p>Characteristics and results of studies of NSAIDs, <italic toggle="yes">n</italic>=11. AKI, acute kidney injury; aOR, adjusted odds ratio; CAD, coronary artery disease; CAM-ICU, Confusion Assessment Method for Intensive Care Unit; CCI, Charlson Comorbidity index; CHF, congestive heart failure; CI, confidence interval; CKD, chronic kidney disease; Cox-2i, Cox-2 selective inhibitor; CV, cardiovascular; CVA, cerebrovascular accident (stroke); CVD, cardiovascular disease; DM, diabetes mellitus; DOSS, Delirium Observation Screening Scale; DRS-R-98, Delirium Rating Scale-Revised-98; EHR, electronic health record; GI, gastrointestinal; GPRD, General Practice Research Database; HIV, human immunodeficiency virus; HR, hazard ratio; HRA, Health Insurance Review and Assessment; HTN, hypertension; IMRD-UK, IQVIA Medical Research Data UK; IQR, interquartile range; JH ADG, John Hopkins Aggregated Diagnosis Group Score; KDIGO, kidney disease improving global outcomes; LCA, latent class analysis; LTC, long-term condition; MI, myocardial infarction; MM, multimorbidity; N/R, not reported; (ns) NSAIDs, (nonselective) nonsteroidal anti-inflammatory drugs; OA, osteoarthritis; OR, odds ratio; PSM, propensity score matching; RA, rheumatoid arthritis; RBC, red blood cell; rDANCAMI, Danish Comorbidity Index for Acute Myocardial Infarction restricted to non-cardiovascular diseases; RR, relative risk; sCr, serum creatinine; <sc>sd</sc>, standard deviation; SLE, systemic lupus erythematous; SNRI, serotonin&#8211;norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TMA, thrombotic microangiopathy; UGI, upper gastrointestinal. &#8727;Age in yr presented as mean (<sc>sd</sc>) unless stated otherwise. <sup>&#8224;</sup>Exposure of interest=i.v. ketorolac hence very unlikely to be any prevalent users. <sup>&#8225;</sup>i2b2 cohort only.</p></caption><alt-text id="alttext0035">Table 4</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="9" rowspan="1"><italic toggle="yes">Studies reporting drug-related harm (secondary care)</italic><hr/></th></tr><tr><th rowspan="2" colspan="1">Reference</th><th rowspan="2" colspan="1">Sample size</th><th colspan="3" rowspan="1">Patient characteristics<hr/></th><th rowspan="2" colspan="1">Analgesic exposure</th><th rowspan="2" colspan="1">Adverse outcome</th><th rowspan="2" colspan="1">Analysis</th><th rowspan="2" colspan="1">Main findings</th></tr><tr><th colspan="1" rowspan="1">Measurement of multimorbidity</th><th colspan="1" rowspan="1">Female <italic toggle="yes">n</italic> (%)</th><th colspan="1" rowspan="1">Age&#8727;</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Glassou and colleagues, 2019<xref rid="bib79" ref-type="bibr"><sup>79</sup></xref></td><td colspan="1" rowspan="1">74&#160;791</td><td colspan="1" rowspan="1">CCI measured over 10 yr before hip fracture. Number of conditions N/R. Outcomes stratified according to MM measure (low/medium/high burden groups based on CCI 0&#8211;1 <italic toggle="yes">vs</italic> 2 <italic toggle="yes">vs</italic> &#8805;3).</td><td colspan="1" rowspan="1">53&#160;337 (71.3)</td><td colspan="1" rowspan="1">N/R (age category by subgroup only).</td><td colspan="1" rowspan="1">Community dispensation data. Current users (&#8805;1 redeemed prescription within 90 days of hip fracture surgery), former users (&#8805;1 prescription 91&#8211;365 days and no prescriptions within 90 days of the hip fracture surgery) <italic toggle="yes">vs</italic> non-users. No dosing information. Prevalent user design.</td><td colspan="1" rowspan="1">Postoperative RBC transfusion within 7 days of hip fracture surgery.</td><td colspan="1" rowspan="1">Cumulative incidence with competing risk of death and log-binomial model adjusted for age, sex, type of fracture, surgery delay, year of surgery, other drug classes, and department.</td><td colspan="1" rowspan="1"><italic toggle="yes">NSAIDs associated with postoperative RBC transfusion in adults with MM:</italic> blood transfusion within 7 days of surgery stratified by MM measure, cumulative incidence, and RR. Current NSAID use <italic toggle="yes">vs</italic> non-use: CCI 0&#8211;1: 43.2% (95% CI 41.6&#8211;44.8%). RR 1.07 (1.02&#8211;1.12); CCI 2: 48.0% (95% CI 46.3&#8211;49.7%). RR 1.06 (1.01&#8211;1.11); CCI &#8805;3: 54.0% (95% CI 51.5&#8211;56.5%). RR 1.09 (1.04&#8211;1.15).</td></tr><tr><td colspan="1" rowspan="1">Gallagher and colleagues, 2012<xref rid="bib78" ref-type="bibr"><sup>78</sup></xref><sup>&#8225;</sup></td><td colspan="1" rowspan="1">1528</td><td colspan="1" rowspan="1">CCI [age adjusted]. Timing and number of conditions N/R. Mean CCI study sub-populations (NSAID exposed 6 <italic toggle="yes">vs</italic> non-exposed 2). Median CCI (IQR) study sub-populations (NSAID 6 [6] vs non-exposed 2 [5])</td><td colspan="1" rowspan="1">1084 (70.9)</td><td colspan="1" rowspan="1">51.8 (15.9)</td><td colspan="1" rowspan="1">&#8805;1 Documented prescription during classified antidepressant treatment period from EHR. Split into chronic (&gt;2 NSAID prescriptions or refills at a daily dose within the study period) or intermittent users. No dosing information. Prevalent user design.</td><td colspan="1" rowspan="1">Treatment-resistant depression defined as remaining depressed despite two or more antidepressant treatments. Timing and follow-up N/R.</td><td colspan="1" rowspan="1">Multivariate logistic regression adjusted for age, sex, race, and insurance payer status (model 1).</td><td colspan="1" rowspan="1"><italic toggle="yes">Non-selective NSAIDs associated with treatment-resistant depression in adults with MM:</italic> ns NSAIDs only: unadjusted OR: 1.74 (95% CI 1.40&#8211;2.18); model 1: OR 1.56 (95% CI 1.23&#8211;1.97). Cox2i: Unadjusted OR 0.83 (95% CI 0.61&#8211;1.12); model 1: OR 0.89 (95% CI 0.65&#8211;1.22). Salicylates: Unadjusted OR 1.01 (95% CI 0.82&#8211;1.25); model 1: OR 1.15 (95% CI 0.91&#8211;1.47).</td></tr><tr><td colspan="1" rowspan="1">Hall and colleagues, 2022<xref rid="bib80" ref-type="bibr"><sup>80</sup></xref></td><td colspan="1" rowspan="1">316</td><td colspan="1" rowspan="1">LTC count. Timing and number of conditions included N/R. Median (IQR) number of LTCs among patients with AKI 1 (0.25&#8211;2) <italic toggle="yes">vs</italic> non-AKI 0 (0&#8211;0).</td><td colspan="1" rowspan="1">191 (60)</td><td colspan="1" rowspan="1">73 (10)</td><td colspan="1" rowspan="1">Exposure definition and measurement N/R. Ketorolac administration, was at the &#8216;discretion of the provider&#8217; (limited to 5 days use). Dose recorded. Prevalent user design<sup>&#8224;</sup>.</td><td colspan="1" rowspan="1">Acute kidney injury defined via KDIGO (i.e. increase in sCr &gt;0.3 mg dl<sup>&#8722;1</sup> within 48 h, or an increase to 1.5 times baseline within the prior 7 days that persists for at least 48 h).</td><td colspan="1" rowspan="1">Multivariable logistic regression and classification and regression tree analysis adjusted for base: loop diuretics, radiocontrast, vasopressors, total number of nephrotoxins, (total number of comorbidities), and average daily ketorolac dose for comparison. Final model: Loop diuretics.</td><td colspan="1" rowspan="1"><italic toggle="yes">MM measure associated with AKI among NSAID exposed adults</italic>: OR base model: Number of comorbidities 3.2 (1.3&#8211;7.7) <italic toggle="yes">P</italic> 0.01. aOR final model: Number of comorbidities OR 2.4 (1.1&#8211;5.2) <italic toggle="yes">P</italic> 0.021. AKI 8/316 (2.5%). AKI patients: Median ketorolac dosing cumulative=37.5 (15&#8211;71) mg. Mean daily dose ketorolac=17.5 (5.3) mg. Median ketorolac doses=2 (1&#8211;4.5). Median duration ketorolac=1 (1&#8211;2) days.</td></tr><tr><td colspan="9" rowspan="1"><bold><italic toggle="yes">Studies reporting drug-related harm (primary and secondary care)</italic></bold></td></tr><tr><td colspan="1" rowspan="1">Abraham and colleagues, 2008<xref rid="bib76" ref-type="bibr"><sup>76</sup></xref></td><td colspan="1" rowspan="1">474&#160;495</td><td colspan="1" rowspan="1">CCI [Deyo] and LTC count. Measured within 1 yr before index prescription. Number of conditions N/R. LTC count of study population: 0&#8211;1: 76.4%; &#8805;2: 23.6%.</td><td colspan="1" rowspan="1">9964 (2.1)</td><td colspan="1" rowspan="1">73 (5.5)</td><td colspan="1" rowspan="1">Prescription fill data via national administrative prescription database. All NSAIDs at &#8216;full musculoskeletal dose&#8217;. New user design.</td><td colspan="1" rowspan="1">All-cause mortality in the 365 days among the older patients who had experienced a UGI endoscopy, MI or CVA after index NSAID prescription.</td><td colspan="1" rowspan="1">Cox proportional hazard analysis with adjustment for age, gender, steroid use, statin use, SSRI use, SNRI use, antianginal use, UGI endoscopy, MI, CVA, history of MI, liver disease, diabetes (type N/R), CHF, CKD, and rheumatological disease.</td><td colspan="1" rowspan="1"><italic toggle="yes">Crude mortality greater in adults with MM compared with those without MM among NSAID users</italic>: 6290 died while exposed to an NSAID (i.e. current users). Of those who died, patients with MM (LTC &#8805;2) 46.3% <italic toggle="yes">vs</italic> patients without MM (LTC 0&#8211;1) 53.7% (<italic toggle="yes">P</italic>&lt;0.001).<break/><italic toggle="yes">MM measure associated with mortality among NSAID exposed adults</italic>: Deyo comorbidity index: 1 HR 1.7 (95% CI 1.5&#8211;1.7); 2 HR 2.2 (95% CI 2.1&#8211;2.4); 3&#8211;4 HR 2.9 (95% CI 2.9 CI 2.7&#8211;3.2); &#8805;4 HR 3.7 (95% CI 3.2&#8211;4.4).</td></tr><tr><td colspan="1" rowspan="1">Stockl and colleagues, 2005<xref rid="bib82" ref-type="bibr"><sup>82</sup></xref></td><td colspan="1" rowspan="1">70&#160;014</td><td colspan="1" rowspan="1">CCI. Measured during the 6 month pre-period. Number of conditions included N/R. CCI study sub-populations CCI mean (<sc>sd</sc>) cox-2i group 0.29 (0.95) <italic toggle="yes">vs</italic> ns NSAID group 0.3 (0.98).</td><td colspan="1" rowspan="1">45&#160;789 (65.4)</td><td colspan="1" rowspan="1">63.4 (16.3)</td><td colspan="1" rowspan="1">Prescription fill data based on pharmacy codes from administrative claims database. Cox-2i or ns NSAIDs. No dosing information. New user design.</td><td colspan="1" rowspan="1">Inpatient hospitalisation for GI bleeding at 1 yr.</td><td colspan="1" rowspan="1">Cox proportional hazards analysis. PSM Cox-2 and non-selective-NSAID initiators matched by age, gender, geographical state, (comorbidity index), steroid use, warfarin use, arthritis indication, history of recent GI bleed. Adjusted for age, gender, state of health plan, pre-period corticosteroid/warfarin use, and pre-period GI bleed/RA/OA indication.</td><td colspan="1" rowspan="1"><italic toggle="yes">MM measure associated with GI bleeding among NSAID exposed adults:</italic> total population: HR CCI 1.11 (95% CI 1.04&#8211;1.18). Low-risk sub-population (<italic toggle="yes">n</italic>=29&#160;547) HR 1.26 (1.08&#8211;1.49); high-risk sub-population (i.e. age &gt;65 yr, recent warfarin or steroid, recent hospitalisation for GI bleeding) (<italic toggle="yes">n</italic>=40&#160;467) HR 1.10 (95% CI 1.03&#8211;1.17).<break/><italic toggle="yes">MM measure associated with GI bleeding after adjustment for pre-period use of a gastroprotective agent:</italic> total population: HR CCI 1.10 (95% CI 1.04&#8211;1.17). Low-risk population: HR CCI 1.30 (95% CI 1.11&#8211;1.51). High-risk population: HR CCI 1.09 (95% CI 1.02&#8211;1.17).</td></tr><tr><td colspan="1" rowspan="1">Cho and colleagues, 2018<xref rid="bib77" ref-type="bibr"><sup>77</sup></xref></td><td colspan="1" rowspan="1">34&#160;120</td><td colspan="1" rowspan="1">CCI measured within 1 yr before RA index date. Number of conditions N/R. Mean (<sc>sd</sc>) CCI study population 3.9 (2.3). Median (IQR) CCI study population 2 (IQR 2&#8211;5).</td><td colspan="1" rowspan="1">26&#160;338 (77.2)</td><td colspan="1" rowspan="1">61.4 (10.9)</td><td colspan="1" rowspan="1">NSAID (ns <italic toggle="yes">vs</italic> Cox-2i) exposure defined as use for &#8805;30 days in the year before CVD developed from HRA national administrative health insurance database. No dosing information. Prevalent user design.</td><td colspan="1" rowspan="1">Cardiovascular disease (i.e. composite of coronary artery disease, haemorrhagic stroke, ischaemic stroke, and peripheral artery disease).</td><td colspan="1" rowspan="1">Multivariate logistic regression. Each case was matched to up to 4 controls for age, sex, RA index date, comorbidities (hypertension, DM, hyperlipidaemia, CKD), and drugs (antiplatelet agents and cholesterol-lowering agents).</td><td colspan="1" rowspan="1"><italic toggle="yes">NSAIDs associated with CV disease in adults with MM:</italic> ns NSAIDs OR 1.32 (95% CI 1.22&#8211;1.41, <italic toggle="yes">P</italic>&lt;0.01). Cox-2 i OR 1.31 (95% CI 1.18&#8211;1.45, <italic toggle="yes">P</italic>&lt;0.01). Simultaneous &#8805;2 NSAIDs OR 1.84 (95% CI 1.66&#8211;2.05, <italic toggle="yes">P</italic>&lt;0.01).<break/><italic toggle="yes">Ns NSAIDs and Cox2i associated with ischaemic stroke in adults with MM</italic>: ns NSAIDs (OR 1.36, 95% CI 1.26&#8211;1.48), Cox-2i (OR 1.33, 95% CI 1.19&#8211;1.49), and simultaneous &#8805;2 NSAIDs (OR 1.96, 95% CI 1.74&#8211;2.20).<break/><italic toggle="yes">Simultaneous use of &#8805;2 NSAIDs associated with haemorrhagic stroke in adults with MM:</italic> simultaneous &#8805;2 NSAIDs OR 1.72 (95% CI 1.27&#8211;2.33).<break/><italic toggle="yes">NSAIDs were not associated with CAD in adults with MM</italic>: ns NSAIDs (OR 1.17, 95% CI 0.97&#8211;1.43), Cox-2i (OR 1.23, 95% CI 0.95&#8211;1.60).</td></tr><tr><td colspan="9" rowspan="1"><bold><italic toggle="yes">Studies not reporting drug-related harm (any setting)</italic></bold></td></tr><tr><td colspan="1" rowspan="1">Bonnesen and colleagues, 2023<xref rid="bib85" ref-type="bibr"><sup>85</sup></xref></td><td colspan="1" rowspan="1">103&#160;308</td><td colspan="1" rowspan="1">rDANCAMI score. Measured based on a 5-yr look back window from cohort entry. 20 Conditions included in MM measure. rDANCAMI of study population: 0: 67%, 1&#8211;3: 22%, 4&#8211;5: 4.2%, &#8805;6: 7.5%.</td><td colspan="1" rowspan="1">44&#160;456 (43)</td><td colspan="1" rowspan="1">62 median (IQR 52&#8211;72)</td><td colspan="1" rowspan="1">Prescription fill data for ibuprofen, naproxen or diclofenac from National Prescription Registry. New user design with time-varying analgesic exposure.</td><td colspan="1" rowspan="1">Primary composite: myocardial infarction, ischaemic stroke, congestive heart failure, atrial fibrillation or flutter, and all-cause death based on linked registry data.</td><td colspan="1" rowspan="1">Pooled logistic regression model weighted by age, sex, baseline rDANCAMI, and baseline drug use to calculate stabilised inverse probability of treatment weights for exposure to ibuprofen, naproxen or diclofenac.</td><td colspan="1" rowspan="1"><italic toggle="yes">No consistent association between NSAID use and composite cardiovascular events stratified by MM measure</italic>: ibuprofen: rDANCAMI score: 0=1.58 (1.35&#8211;1.86); score 1&#8211;3=1.39 (1.12&#8211;1.73); score 4&#8211;5=1.29 (0.82&#8211;2.04); score &#8805;6=1.33 (1.02&#8211;1.75).<break/>Naproxen: rDANCAMI score: 0=1.68 (0.83&#8211;3.38); score 1&#8211;3=1.48 (0.61&#8211;3.61); score 4&#8211;5=unable to compare (too few events); score &#8805;6=0.01 (0.00&#8211;0.10).<break/>Diclofenac: rDANCAMI score: 0=3.77 (2.49&#8211;5.71); score 1&#8211;3=2.09 (1.10&#8211;3.99); score 4&#8211;5=0.73 (0.19&#8211;2.78); score &#8805;6=0.91 (0.36&#8211;2.28).</td></tr><tr><td colspan="1" rowspan="1">Liu and colleagues, 2018<xref rid="bib81" ref-type="bibr"><sup>81</sup></xref></td><td colspan="1" rowspan="1">190</td><td colspan="1" rowspan="1">JH ADG score measured within 5 yr before index date. Number of conditions used N/R. MM measure of sub-populations: TMA positive (ADG mean 14 [<sc>sd</sc> 3.43], median 14 [IQR 12&#8211;16]) <italic toggle="yes">vs</italic> TMA negative (ADG mean 12 [<sc>sd</sc> 3.77], median 12 [IQR 9&#8211;15]).</td><td colspan="1" rowspan="1">120 (63.2)</td><td colspan="1" rowspan="1">67 (16)</td><td colspan="1" rowspan="1">Drug dispensation data from administrative database. &#8805;1 NSAID or acetaminophen dispensed (dichotomised as NSAID [exposed] <italic toggle="yes">vs</italic> acetaminophen [unexposed]) during study dates. No dosing information. Prevalent user design.</td><td colspan="1" rowspan="1">TMA hospitalisation/diagnosis within 1.5 times the variable &#8216;day supply&#8217; after prescription start date.</td><td colspan="1" rowspan="1">Unadjusted results<break/><italic toggle="yes">NB: cases matched to controls based on</italic> age, sex, index date, rural residence, neighbourhood income quintile and conditions, and drugs associated with TMA (malignant HTN, SLE, HIV, sepsis, quetiapine, tacrolimus, sirolimus, cyclosporine, clopidogrel, and ticlopidine).</td><td colspan="1" rowspan="1"><italic toggle="yes">NSAIDs associated with a relative reduction in occurrence of TMA among MM adults:</italic> 19/38 cases (50%) had recent exposure to NSAIDs. 115/152 Controls (76%) had recent exposure to NSAIDs. Unadjusted OR: paracetamol=1.0 (ref). NSAIDs 0.32 (95% CI 0.15&#8211;0.69).</td></tr><tr><td colspan="1" rowspan="1">Yamanashi and colleagues, 2023<xref rid="bib83" ref-type="bibr"><sup>83</sup></xref></td><td colspan="1" rowspan="1">1274</td><td colspan="1" rowspan="1">CCI measured at study enrolment. Number of conditions N/R. Mean (<sc>sd</sc>) CCI study population 3.3 (3). Mean (<sc>sd</sc>) CCI sub-populations, NSAID group 2.8 (2.9), no NSAID 3.6 (2.9).</td><td colspan="1" rowspan="1">619 (48.6)</td><td colspan="1" rowspan="1">68.8 (13.6)</td><td colspan="1" rowspan="1">Medication use history for NSAIDs by study enrolment based on EHR. No dosing information. Prevalent user design.</td><td colspan="1" rowspan="1">Delirium based on any questionnaire (i.e. DOSS/DRS-R-98/CAM-ICU) screening positive or clinical description in medical record showing the evidence of confusion or mental status change consistent with delirium. Assessed on admission/study enrolment.</td><td colspan="1" rowspan="1">Multivariate logistic regression adjusted for age, sex, dementia status, hospitalisation department, aspirin, (NSAIDs), glucosamine, and other anti-inflammatory drugs.</td><td colspan="1" rowspan="1"><italic toggle="yes">NSAIDs not associated with delirium in adults with MM</italic>: crude event rate for delirium: NSAID group: 101/439 (23%) <italic toggle="yes">vs</italic> no NSAID group: 292/835 (35%). NSAIDs OR 0.76 (95% CI 0.55&#8211;1.03) <italic toggle="yes">P</italic> 0.077.<break/><italic toggle="yes">Meloxicam associated with a reduction in delirium in adults with MM</italic>: individual types of NSAID: in the analysis using all subjects (<italic toggle="yes">n</italic>=1274), meloxicam was significantly associated with a lower risk of delirium (OR: 0.46, 95% CI 0.22&#8211;0.97, <italic toggle="yes">P</italic>=0.04) while other individual NSAIDs were not.</td></tr><tr><td colspan="1" rowspan="1">Humes and colleagues, 2011<xref rid="bib75" ref-type="bibr"><sup>75</sup></xref></td><td colspan="1" rowspan="1">9879</td><td colspan="1" rowspan="1">CCI measured 1 month before index. Number of conditions N/R. MM measure of sub-populations: cases CCI 0: 357 (39.71%). CCI 1: 215 (23.92%). CCI &#8805;2: 327 (36.37%) <italic toggle="yes">vs</italic> controls: CCI 0: 5133 (57.16%). CCI 1: 1867 (20.79%). CCI &#8805;2: 1980 (22.05%).</td><td colspan="1" rowspan="1">6065 (61.4)</td><td colspan="1" rowspan="1">N/R (category only).</td><td colspan="1" rowspan="1">Prescription fill data from UK GPRD database. Current users=prescription of a drug in the 6 months before index. Ever users=prescription at any time before this 6-month window without a current prescription. No dosing information. Prevalent user design.</td><td colspan="1" rowspan="1">Free diverticular perforation via GPRD coding anytime during study period (1990&#8211;2005).</td><td colspan="1" rowspan="1">Multivariate logistic regression adjusted for age and sex.</td><td colspan="1" rowspan="1"><italic toggle="yes">NSAID use not associated with free diverticular perforation amongst adults with or without MM:</italic> stratum specific OR (95% CI) by CCI for NSAID use NSAID current <italic toggle="yes">vs</italic> never: CCI 0: 1.48 (95% CI 0.81&#8211;2.71), CCI 1: 1.32 (95% CI 0.55&#8211;3.14), CCI &#8805;2: 1.90 (95% CI 0.89&#8211;4.06).</td></tr><tr><td colspan="1" rowspan="1">Zemedikun and colleagues, 2022<xref rid="bib74" ref-type="bibr"><sup>74</sup></xref></td><td colspan="1" rowspan="1">661&#160;499</td><td colspan="1" rowspan="1">Measured by LTC count any time before diagnosis of OA based on 30 diseases. LTC median (IQR) study sub-populations OA group LTC 2 (1&#8211;4) <italic toggle="yes">vs</italic> non-OA group LTC 1 (0&#8211;3)</td><td colspan="1" rowspan="1">396&#160;802 (60.0)</td><td colspan="1" rowspan="1">62.8 (12.4)</td><td colspan="1" rowspan="1">Prescription data from IMRD-UK EHR database. No dosing information. Prevalent user design.</td><td colspan="1" rowspan="1">All-cause mortality anytime during follow-up post lag period of 1 yr from index date (maximum 9 yr).</td><td colspan="1" rowspan="1">Cox proportional hazard analysis with LCA matched 1:1 (based on age, sex, and general practice) adjusted for comorbidity phenotypes, age, sex, BMI categories, deprivation quintiles, smoking status, and ethnicity.</td><td colspan="1" rowspan="1"><italic toggle="yes">NSAIDs associated with a reduction in mortality in adults with MM</italic>: cases (i.e. MM): no opioid (reference); NSAIDs HR 0.95 (95% CI 0.93&#8211;0.98).<break/><italic toggle="yes">NSAIDs not associated with mortality in adults without MM:</italic> controls (i.e. non-MM): no opioid (reference); NSAIDs HR 1.04 (95% CI 0.99&#8211;1.10).</td></tr></tbody></table></table-wrap></p><sec id="sec2.7.1"><title>Evidence of drug-related harm (n=6)</title><sec id="sec2.7.1.1"><title>Secondary care settings (n=3)</title><p id="p0145">Three studies using secondary care datasets reported analgesic-related harms (i.e. postoperative blood transfusion, treatment-resistant depression and AKI),<xref rid="bib78" ref-type="bibr">78</xref>, <xref rid="bib79" ref-type="bibr">79</xref>, <xref rid="bib80" ref-type="bibr">80</xref> two of which were based on hospital inpatients.<xref rid="bib79" ref-type="bibr"><sup>79</sup></xref><sup>,</sup><xref rid="bib80" ref-type="bibr"><sup>80</sup></xref> Current NSAID use compared with non-use was associated with a modest increase in red cell transfusion within 7 days of hip fracture corrective surgery among older adults (&#8805;65 yr) with multimorbidity.<xref rid="bib79" ref-type="bibr"><sup>79</sup></xref> Non-selective NSAIDs, but not cyclooxygenase-2 (COX-2) inhibitors, were associated with an increased risk of treatment-resistant depression among outpatients with multimorbidity and major depression. However, analgesic exposure was based on a single prescription.<xref rid="bib78" ref-type="bibr"><sup>78</sup></xref> Multimorbidity (i.e. LTC count) was associated with an increased risk of AKI at 7 days in older adults (&#8805;60 yr) who received i.v. ketorolac for pain during hospital admission after traumatic injury. The absolute number of AKI episodes was low and many confounders were not considered.<xref rid="bib80" ref-type="bibr"><sup>80</sup></xref></p></sec><sec id="sec2.7.1.2"><title>Primary and secondary care settings (n=3)</title><p id="p0150">Three studies used primary and secondary care data to assess adverse outcomes (i.e. gastrointestinal [GI] bleeding, cardiovascular disease, and death after NSAID-associated event) among outpatient NSAID users.<xref rid="bib76" ref-type="bibr"><sup>76</sup></xref><sup>,</sup><xref rid="bib77" ref-type="bibr"><sup>77</sup></xref><sup>,</sup><xref rid="bib82" ref-type="bibr"><sup>82</sup></xref> Multimorbidity (increasing Deyo comorbidity index score) was an independent predictor of death after an NSAID-associated event (i.e. upper GI endoscopy, myocardial infarction or stroke) among older veterans.<xref rid="bib76" ref-type="bibr"><sup>76</sup></xref> Multimorbidity (increasing CCI) had a modest predictive effect on GI bleeding in adults treated with NSAIDs, which was more pronounced among a low-risk sub-population (i.e. age &lt;65 yr, no recent warfarin or steroid treatment or recent GI bleed).<xref rid="bib82" ref-type="bibr"><sup>82</sup></xref> Non-selective NSAIDs, COX-2 inhibitors, and simultaneous use of &#8805;2 NSAIDs were associated with an increased risk of composite cardiovascular disease compared with non-use among a multimorbid population of adults with rheumatoid arthritis.<xref rid="bib77" ref-type="bibr"><sup>77</sup></xref></p></sec></sec><sec id="sec2.7.2"><title>No evidence of drug-related harm (n=5)</title><p id="p0155">Five studies reported no clear evidence of harm associated with NSAIDs among adults with multimorbidity including cardiovascular events, thrombotic microangiopathy (TMA), delirium, diverticular perforation, and mortality.<xref rid="bib74" ref-type="bibr"><sup>74</sup></xref><sup>,</sup><xref rid="bib75" ref-type="bibr"><sup>75</sup></xref><sup>,</sup><xref rid="bib81" ref-type="bibr"><sup>81</sup></xref><sup>,</sup><xref rid="bib83" ref-type="bibr"><sup>83</sup></xref><sup>,</sup><xref rid="bib85" ref-type="bibr"><sup>85</sup></xref> A population-based study of adults with type 2 diabetes showed no graded increase in the association between NSAID use and composite cardiovascular events when stratified by multimorbidity measure (i.e. rDANCAMI score).<xref rid="bib85" ref-type="bibr"><sup>85</sup></xref> Two studies used secondary care datasets to assess hospital inpatients.<xref rid="bib81" ref-type="bibr"><sup>81</sup></xref><sup>,</sup><xref rid="bib83" ref-type="bibr"><sup>83</sup></xref> NSAIDs were associated with a relative reduction in the odds of hospitalisation for TMA compared with paracetamol. TMA was a rare event in the study population.<xref rid="bib81" ref-type="bibr"><sup>81</sup></xref> NSAIDs were not associated with delirium amongst a population of older, multimorbid volunteers, however, in drug-specific analysis, meloxicam use was associated with a lower risk of delirium.<xref rid="bib83" ref-type="bibr"><sup>83</sup></xref> Finally, two studies based in UK primary care compared current <italic toggle="yes">vs</italic> no NSAID use in sub-populations with multimorbidity.<xref rid="bib74" ref-type="bibr"><sup>74</sup></xref><sup>,</sup><xref rid="bib75" ref-type="bibr"><sup>75</sup></xref> One showed no association between use and free diverticular perforation in the sub-population with multimorbidity.<xref rid="bib75" ref-type="bibr"><sup>75</sup></xref> While the other reported NSAIDs were associated with a marginal reduction in mortality among a sub-population of adults with multimorbidity compared with no association among a sub-population of adults without multimorbidity.<xref rid="bib74" ref-type="bibr"><sup>74</sup></xref></p></sec></sec><sec id="sec2.8"><title>Gabapentinoids</title><p id="p0160">Characteristics of the single study reporting gabapentinoids are summarised in <xref rid="tbl5" ref-type="table">Table&#160;5</xref>. Postoperative gabapentin use compared with non-use was associated with delirium and pneumonia, but not mortality in adults with multiple LTCs (i.e. combined comorbidity index &#8805;4).<xref rid="bib84" ref-type="bibr"><sup>84</sup></xref><table-wrap position="float" id="tbl5" orientation="portrait"><label>Table 5</label><caption><p>Characteristics and results of studies of gabapentinoids. CCIn, combined comorbidity index; CI, confidence interval; CT, computed tomography; MM, multimorbidity; N/R, not reported; POD, postoperative day; PSM, propensity score matching; RD, risk difference; RR, relative risk; <sc>sd</sc>, standard deviation. &#8727;Crude numbers refer to those pre-PSM (i.e. propensity score matching). <sup>&#8224;</sup>Age in yr presented as mean (<sc>sd</sc>).</p></caption><alt-text id="alttext0040">Table 5</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Reference</th><th rowspan="2" colspan="1">Sample size</th><th colspan="3" rowspan="1">Patient characteristics<hr/></th><th rowspan="2" colspan="1">Analgesic exposure</th><th rowspan="2" colspan="1">Adverse outcome</th><th rowspan="2" colspan="1">Analysis</th><th rowspan="2" colspan="1">Main findings</th></tr><tr><th colspan="1" rowspan="1">Measurement of multimorbidity</th><th colspan="1" rowspan="1">Female, <italic toggle="yes">n</italic> (%)</th><th colspan="1" rowspan="1">Age<sup>&#8224;</sup></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Park and colleagues, 2022<xref rid="bib84" ref-type="bibr"><sup>84</sup></xref></td><td colspan="1" rowspan="1">967&#160;547<sup>&#8727;</sup></td><td colspan="1" rowspan="1">Combined comorbidity index. Timing and number of conditions: N/R. Compared MM <italic toggle="yes">vs</italic> non-MM (index &#8805;4 <italic toggle="yes">vs</italic> &lt;4). Mean comorbidity index (<sc>sd</sc>) of sub-populations: gabapentin group 1.2 (2.2) and no gabapentin group 1.8 (2.6).</td><td colspan="1" rowspan="1">576&#160;658 (59.6)</td><td colspan="1" rowspan="1">76.2 (7.4)</td><td colspan="1" rowspan="1">Charge codes (i.e. medications for billing and reimbursement) on POD 0, 1 or 2 from nationwide administrative database. Total daily gabapentin dose in milligrams given during the exposure defining period (i.e. POD 0, 1, and 2). New user design.</td><td colspan="1" rowspan="1">In-hospital death. Delirium including explicit (i.e. delirium is directly mentioned) and implicit (e.g. encephalopathy) criteria. Pneumonia via diagnostic code+i.v. antibiotic use or CT chest. All outcomes determined until hospital discharge.</td><td colspan="1" rowspan="1">Multivariable logistic regression models. Gabapentin <italic toggle="yes">vs</italic> no gabapentin via PSM which included patient characteristic information, insurance type, admission characteristics, surgery type, (combined comorbidity score), comorbidities, inpatient medication use, and procedures before or on POD 2, hospital-level characteristics, geographic region, and calendar year.</td><td colspan="1" rowspan="1"><italic toggle="yes">Gabapentin has no association with in-hospital mortality in subgroups with or without MM</italic>. Gabapentin <italic toggle="yes">vs</italic> non-gabapentin: CCI &lt;4: RR 0.88 (95% CI 0.67&#8211;1.15); CCI &#8805;4: RR 1.05 (95% CI 0.88&#8211;1.24).<break/><italic toggle="yes">Gabapentin associated with delirium in subgroups with and without MM.</italic> Gabapentin <italic toggle="yes">vs</italic> non-gabapentin CCI &lt;4: RR 1.2 (95% CI 1.13&#8211;1.27). CCI &#8805;4: RR 1.4 (95% CI 1.30&#8211;1.51). RD 0.41 (95% CI 0.28&#8211;0.53) <italic toggle="yes">vs</italic> 2.66 (95% CI 2.08&#8211;3.24) per 100 persons; <italic toggle="yes">P</italic>&lt;0.001 for heterogeneity.<break/><italic toggle="yes">Gabapentin associated with pneumonia in subgroups with and without MM.</italic> Gabapentin <italic toggle="yes">vs</italic> non-gabapentin CCI &lt;4: RR 1.22 (95% CI 1.10&#8211;1.35). CCI &#8805;4: RR 1.19 (95% CI 1.07&#8211;1.33). RD 0.15 [95% CI 0.07&#8211;0.22] <italic toggle="yes">vs</italic> 0.66 (0.25&#8211;1.07) per 100 persons; <italic toggle="yes">P</italic>=0.02 for heterogeneity.</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="sec3"><title>Discussion</title><p id="p0165">This review identified 27 studies that reported harms from opioids, gabapentinoids or NSAIDs prescribed for pain in adults with multimorbidity, or the impact of multimorbidity on adverse outcomes among adults prescribed analgesics. Studies were heterogenous in their study design and of variable quality. Few reported absolute adverse event rates and data on analgesic dosing were often absent. Opioid use, compared with non-use, was associated with increased mortality among adults with multimorbidity. Multimorbidity, by different measures, was associated with opioid overdose, abuse, and mortality among adults prescribed opioids for pain. Half of studies of NSAIDs (six out of 11) reported drug-related harms across different outcome measures. Only one study reported the risks of gabapentinoids, which found an association with delirium and pneumonia, but not death, among adults with multiple LTCs.</p><p id="p0170">Chronic pain leads to reduced quality of life,<xref rid="bib87" ref-type="bibr"><sup>87</sup></xref><sup>,</sup><xref rid="bib88" ref-type="bibr"><sup>88</sup></xref> which itself is the highest ranked patient-reported outcome amongst adults with multimorbidity.<xref rid="bib89" ref-type="bibr"><sup>89</sup></xref> Optimal pain management requires a comprehensive assessment to determine aetiology, timing (e.g. acute or chronic) and classification (e.g. primary or secondary). The complexity of chronic pain management is compounded by psychiatric, psychological, and medical comorbidities<xref rid="bib90" ref-type="bibr"><sup>90</sup></xref> with associated polypharmacy. Cardiovascular, neurological, musculoskeletal, gastrointestinal, and mental health conditions predict higher levels of pain in adults with multimorbidity<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="bib11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> with corresponding implications for treatment. There is a clear biological rationale for altered analgesic pharmacokinetics among certain physical comorbidities (e.g. reduced renal clearance of opioid metabolites in chronic kidney disease),<xref rid="bib91" ref-type="bibr"><sup>91</sup></xref> however, mechanisms are less well defined in psychiatric illness (e.g. responsiveness to opioid analgesics in depression/anxiety).<xref rid="bib92" ref-type="bibr"><sup>92</sup></xref> Recent evidence has highlighted the importance of adverse childhood experiences (ACEs) on the development of multimorbidity,<xref rid="bib93" ref-type="bibr"><sup>93</sup></xref> chronic pain, and major depression<xref rid="bib94" ref-type="bibr"><sup>94</sup></xref> in adulthood. ACEs also increase the risk of prescription opioid misuse.<xref rid="bib95" ref-type="bibr"><sup>95</sup></xref> Despite an understanding of the translational mechanisms of analgesic properties, there is limited evidence of the relationships among different disease and drug clusters to guide clinicians when managing pain in patients with multimorbidity.<xref rid="bib96" ref-type="bibr"><sup>96</sup></xref></p><p id="p0175">Opioid use has increased dramatically in recent decades.<xref rid="bib97" ref-type="bibr"><sup>97</sup></xref><sup>,</sup><xref rid="bib98" ref-type="bibr"><sup>98</sup></xref> Data from UK primary care highlights a five-fold and 30-fold increase in codeine and oxycodone prescribing, respectively, for non-cancer pain from 2006 to 2017,<xref rid="bib97" ref-type="bibr"><sup>97</sup></xref> with 18% of the Scottish population being prescribed an opioid in 2012.<xref rid="bib99" ref-type="bibr"><sup>99</sup></xref> Multimorbidity increases the likelihood of persistent use after first prescription<xref rid="bib100" ref-type="bibr">100</xref>, <xref rid="bib101" ref-type="bibr">101</xref>, <xref rid="bib102" ref-type="bibr">102</xref>, <xref rid="bib103" ref-type="bibr">103</xref>, <xref rid="bib104" ref-type="bibr">104</xref> and people with multiple LTCs are over-represented among patients receiving strong opioids.<xref rid="bib97" ref-type="bibr"><sup>97</sup></xref> One in five adults newly prescribed very high doses of opioids (i.e. &gt;200 MME per day) remain on such doses for at least 2 years,<xref rid="bib97" ref-type="bibr"><sup>97</sup></xref> emphasising the importance of understanding long-term drug-related harms, particularly as trials both under-report adverse events<xref rid="bib105" ref-type="bibr"><sup>105</sup></xref> and are usually limited to short-term outcomes.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref><sup>,</sup><xref rid="bib105" ref-type="bibr"><sup>105</sup></xref> Randomised controlled trials of opioids for chronic non-cancer pain exclude patients with past or present substance use disorder or active mental illness, despite the high prevalence of both, amongst patients prescribed opioids.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref><sup>,</sup><xref rid="bib106" ref-type="bibr"><sup>106</sup></xref><sup>,</sup><xref rid="bib107" ref-type="bibr"><sup>107</sup></xref> Qualitative evidence among patients with multiple LTCs and chronic pain highlights concerns related to both opioid harms (e.g. dose titration, addiction, and overmedication) and potential undertreatment (e.g. barriers to access).<xref rid="bib108" ref-type="bibr"><sup>108</sup></xref></p><p id="p0180">This review is the first to our knowledge to synthesise evidence on the risks of analgesics in adults with multimorbidity. Multimorbidity is a relatively novel concept in health research which is reflected in the small number of studies included in our review. The absence of evidence, particularly from primary care settings, is an important finding. However, we adopted an extensive and systematic search of the literature and considered a large proportion of full-text reviews in an attempt to ensure adequate capture of multimorbidity and adverse events given under-reporting in titles/abstracts.<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref> In addition, this review included a broad range of potential drug-related harms and highlights clear limitations in the available evidence.</p><p id="p0185">This review has limitations. The focus was to establish adverse analgesic-related outcomes without measuring benefits, however, syntheses of benefits and harms in reviews frequently under-represent the latter.<xref rid="bib109" ref-type="bibr"><sup>109</sup></xref> Limitations in the synthesis reflect limitations in the primary literature (e.g. lack of adjustment for confounding by indication) as is common in many reviews of harms.<xref rid="bib110" ref-type="bibr"><sup>110</sup></xref> The review included a broad range of studies from a variety of settings with differences in exposures, comparators, and outcomes. As such, statistical synthesis was not possible and narrative synthesis was challenging. This heterogeneity was thought to reflect the literature on multimorbidity and the breadth of the review question which aimed to synthesise knowledge for an underserved population using an explorative, hypothesis-generating approach. However, it is difficult to draw definitive conclusions from these findings and further work of sufficient granularity, in particular in regard to specific inclusion of individual comorbidities, is required. Some studies were included based on a population or sub-population mean who were multimorbid (as defined by a recommended measure of multimorbidity). Furthermore, multimorbidity was deduced from a CCI of greater than two for some studies despite CCI score weighting for condition severity.<xref rid="bib111" ref-type="bibr"><sup>111</sup></xref> However, CCI is one of the most commonly used and validated measures of multimorbidity.<xref rid="bib44" ref-type="bibr"><sup>44</sup></xref><sup>,</sup><xref rid="bib111" ref-type="bibr">111</xref>, <xref rid="bib112" ref-type="bibr">112</xref>, <xref rid="bib113" ref-type="bibr">113</xref> Other definitions based on proxy measures of multimorbidity (e.g. RUB 3&#8211;5) were used. The findings may therefore contain adults with and without multimorbidity hence diluting reported relationships between multimorbidity and analgesic-related harms. However, our approach was adopted to be intentionally inclusive to draw conclusions in an area which is understudied. The review did not include paracetamol as it is usually purchased over the counter and we considered it to have limited harms when used at an appropriate dose.<xref rid="bib114" ref-type="bibr"><sup>114</sup></xref> However, recent evidence suggestive of harms amongst older adults<xref rid="bib115" ref-type="bibr"><sup>115</sup></xref> merits further study. Antidepressants were not included as the primary indication is for depressive symptoms rather than pain. Finally, results of studies which comprised mutual adjustment for both the relevant analgesic and multimorbidity measure (hence removing the ability to isolate the relationship of interest) could not be included.</p><p id="p0190">Guidelines recommend that treatment strategies for chronic pain should be individualised and multimodal including exercise programmes, psychological therapy, and pharmacotherapy with multidisciplinary co-ordination.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref><sup>,</sup><xref rid="bib116" ref-type="bibr"><sup>116</sup></xref> Our review highlights the potential for harms from drug treatments in people with multimorbidity, emphasising the need for a holistic, patient-centred approach incorporating physical and mental health rather than a disease-specific focus.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib8" ref-type="bibr"><sup>8</sup></xref></p><p id="p0195">Studies have reported adverse outcomes associated with polypharmacy in people with multimorbidity,<xref rid="bib117" ref-type="bibr">117</xref>, <xref rid="bib118" ref-type="bibr">118</xref>, <xref rid="bib119" ref-type="bibr">119</xref> however, our review highlights a lack of evidence relating to analgesic harms. This discrepancy may reflect the challenges of designing a robust pharmacoepidemiological study with an appropriate active comparator group to ensure confounding by indication is avoided. Randomised controlled trials are needed which actively recruit adults with multiple LTCs and report absolute event rates alongside benefits with a focus on health-related quality of life, mental health outcomes, and mortality.<xref rid="bib89" ref-type="bibr"><sup>89</sup></xref> Routinely collected data offer an opportunity to understand adverse drug events in real-world settings using large populations to generate timely evidence for limited cost.<xref rid="bib120" ref-type="bibr"><sup>120</sup></xref> Novel epidemiological techniques, such as target trial emulation,<xref rid="bib121" ref-type="bibr"><sup>121</sup></xref> using real-world data may allow quantification of long-term analgesic outcomes while minimising the impact of common sources of bias (e.g. prevalent user) by adopting a causal inference approach. Studies are needed particularly in relation to harms associated with NSAIDs and gabapentinoids among people with multimorbidity given the lack of evidence. Future studies should include clear definition and measurement of multimorbidity and adopt approaches that are consistent with consensus opinion including reporting the prevalence of individual co-existent conditions.<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref> This would allow identification of specific patterns of LTCs (e.g. mental&#8211;physical multimorbidity) which may confer greater risk of adverse analgesic-related outcomes. Health policy must re-orientate to account for multimorbidity given that patients with multiple LTCs account for more than half of primary and secondary care costs.<xref rid="bib122" ref-type="bibr"><sup>122</sup></xref></p><p id="p0200">Pain is a common and debilitating symptom in patients with multimorbidity. Optimal management strategies are currently unknown, but despite these evidence gaps, analgesic use is widespread. Our review summarises the available evidence on the risks of analgesics in adults with multimorbidity suggesting the need for caution when prescribing opioids because of a potentially increased risk of overdose and mortality. There is a pressing need for research which addresses the benefits and harms of pain management, specifically NSAIDs and gabapentinoids, in adults with multiple LTCs. Such evidence would inform an individualised risk prediction approach accounting for complex disease&#8211;disease and disease&#8211;drug interactions, empowering both healthcare providers and people living with multimorbidity to make informed decisions about their healthcare.</p></sec><sec id="sec4"><title>Authors&#8217; contributions</title><p id="p0205">Research idea and design: SB, CHG, PBM, LAC</p><p id="p0210">Data acquisition: CHG, HW</p><p id="p0215">Data interpretation: CHG, HW, KB, SB</p><p id="p0220">Data synthesis: CHG, SB</p><p id="p0225">Supervision: SB, PBM, LAC</p><p id="p0230">Contributed important intellectual content during manuscript drafting or revision: all authors</p><p id="p0235">Agree to be accountable for integrity of the work and will ensure that questions pertaining to the accuracy or integrity of any portion of the work, are appropriately resolved: CHG, SB</p><p id="p0240">Approved the final manuscript: all authors</p></sec><sec id="sec5"><title>Funding</title><p id="p0245">CHG and HW are each funded separately by PhD scholarships at the <funding-source id="gs1">University of Dundee &amp; the University of Glasgow</funding-source>, respectively, as part of the Multimorbidity PhD Programme for Health Professionals supported by the <funding-source id="gs2">Wellcome Trust (HW grant number: 223499/Z/22/Z)</funding-source>. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Declarations of interest</title><p id="p0250">CHG, HW, and KB declare that they have no conflicts of interest. Outside the submitted work PBM has received honoraria for lectures and advisory boards from AstraZeneca, Vifor, Pharmacosmos, Astellas, GlaxoSmithKline (GSK), Bayer, and Boehringer Ingelheim and research funding from AstraZeneca and Boehringer Ingelheim. SB has received consultancy fees from AstraZeneca, GSK, and Bayer and research funding from AstraZeneca. LAC receives research support funding, on behalf of her institution, from the Advanced Pain Discovery Platform (funded by UK Research and Innovation, Versus Arthritis, Eli Lilly), the Scottish Government (Chief Scientist Office), The Wellcome Trust, and the National Institute of Academic Anaesthesia. She is Vice Chair of SIGN Council and is currently chairing the SIGN Guideline Development Group for Management of Chronic Pain.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="book" id="sref1"><person-group person-group-type="author"><collab>NICE</collab></person-group><part-title>Multimorbidity: clinical assessment and management</part-title><year>2017</year><publisher-name>National Institute for Health and Care Excellence</publisher-name><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.nice.org.uk/guidance/ng56" id="intref0010a">https://www.nice.org.uk/guidance/ng56</ext-link></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="book" id="sref2"><person-group person-group-type="author"><collab>Academy of Medical Sciences</collab></person-group><part-title>Multimorbidity: a priority for global health research</part-title><year>2018</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://acmedsci.ac.uk/file-download/82222577" id="intref0010b">https://acmedsci.ac.uk/file-download/82222577</ext-link></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Chowdhury</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Chandra Das</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sunna</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Beyene</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>A.</given-names></name></person-group><article-title>Global and regional prevalence of multimorbidity in the adult population in community settings: a systematic review and meta-analysis</article-title><source>EClinicalMedicine</source><volume>57</volume><year>2023</year><object-id pub-id-type="publisher-id">101860</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2023.101860</pub-id><pub-id pub-id-type="pmcid">PMC9971315</pub-id><pub-id pub-id-type="pmid">36864977</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Manolova</surname><given-names>G.</given-names></name><name name-style="western"><surname>Daskalopoulou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vitoratou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Prince</surname><given-names>M.</given-names></name><name name-style="western"><surname>Prina</surname><given-names>A.M.</given-names></name></person-group><article-title>Prevalence of multimorbidity in community settings: a systematic review and meta-analysis of observational studies</article-title><source>J&#160;Comorb</source><volume>9</volume><year>2019</year><object-id pub-id-type="publisher-id">2235042x19870934</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2235042X19870934</pub-id><pub-id pub-id-type="pmcid">PMC6710708</pub-id><pub-id pub-id-type="pmid">31489279</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Barnett</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mercer</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Norbury</surname><given-names>M.</given-names></name><name name-style="western"><surname>Watt</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wyke</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guthrie</surname><given-names>B.</given-names></name></person-group><article-title>Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study</article-title><source>Lancet</source><volume>380</volume><year>2012</year><fpage>37</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">22579043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(12)60240-2</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Makovski</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Schmitz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zeegers</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Stranges</surname><given-names>S.</given-names></name><name name-style="western"><surname>van den Akker</surname><given-names>M.</given-names></name></person-group><article-title>Multimorbidity and quality of life: systematic literature review and meta-analysis</article-title><source>Ageing Res Rev</source><volume>53</volume><year>2019</year><object-id pub-id-type="publisher-id">100903</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2019.04.005</pub-id><pub-id pub-id-type="pmid">31048032</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Jani</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Hanlon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nicholl</surname><given-names>B.I.</given-names></name><etal/></person-group><article-title>Relationship between multimorbidity, demographic factors and mortality: findings from the UK Biobank cohort</article-title><source>BMC Med</source><volume>17</volume><year>2019</year><fpage>74</fpage><pub-id pub-id-type="pmid">30967141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-019-1305-x</pub-id><pub-id pub-id-type="pmcid">PMC6456941</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="editor"><name name-style="western"><surname>Medicine</surname><given-names>P.L.O.S.</given-names></name></person-group><issue-title>Multimorbidity: addressing the next global pandemic</issue-title><source>PLoS Med</source><volume>20</volume><year>2023</year><object-id pub-id-type="publisher-id">e1004229</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.1004229</pub-id><pub-id pub-id-type="pmcid">PMC10072481</pub-id><pub-id pub-id-type="pmid">37014909</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Skou</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Mair</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Fortin</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Multimorbidity</article-title><source>Nat Rev Dis Primers</source><volume>8</volume><year>2022</year><fpage>48</fpage><pub-id pub-id-type="pmid">35835758</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-022-00376-4</pub-id><pub-id pub-id-type="pmcid">PMC7613517</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>McQueenie</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jani</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Siebert</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Prevalence of chronic pain in LTCs and multimorbidity: a cross-sectional study using UK Biobank</article-title><source>J&#160;Multimorb Comorb</source><volume>11</volume><year>2021</year><object-id pub-id-type="publisher-id">26335565211005870</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/26335565211005870</pub-id><pub-id pub-id-type="pmcid">PMC8728767</pub-id><pub-id pub-id-type="pmid">35004337</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Scherer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gensichen</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Association between multimorbidity patterns and chronic pain in elderly primary care patients: a cross-sectional observational study</article-title><source>BMC Fam Pract</source><volume>17</volume><year>2016</year><fpage>68</fpage><pub-id pub-id-type="pmid">27267905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12875-016-0468-1</pub-id><pub-id pub-id-type="pmcid">PMC4895952</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Onder</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vetrano</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Italian guidelines on management of persons with multimorbidity and polypharmacy</article-title><source>Aging Clin Exp Res</source><volume>34</volume><year>2022</year><fpage>989</fpage><lpage>996</lpage><pub-id pub-id-type="pmid">35249211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40520-022-02094-z</pub-id><pub-id pub-id-type="pmcid">PMC9135855</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><article-title>Guiding principles for the care of older adults with multimorbidity: an approach for clinicians: American geriatrics society expert panel on the care of older adults with multimorbidity</article-title><source>J&#160;Am Geriatr Soc</source><volume>60</volume><year>2012</year><fpage>E1</fpage><lpage>E25</lpage><pub-id pub-id-type="pmid">22994865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1532-5415.2012.04188.x</pub-id><pub-id pub-id-type="pmcid">PMC4450364</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="other" id="sref14"><person-group person-group-type="author"><collab>NICE clinical guideline 193</collab></person-group><article-title>Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain</article-title><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.nice.org.uk/guidance/ng193" id="intref0015">https://www.nice.org.uk/guidance/ng193</ext-link><year>2021</year><pub-id pub-id-type="pmid">33939353</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="other" id="sref15"><person-group person-group-type="author"><collab>SIGN clinical guideline 136</collab></person-group><article-title>Management of chronic pain. Health improvement scotland</article-title><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.sign.ac.uk/assets/sign136.pdf" id="intref0020">https://www.sign.ac.uk/assets/sign136.pdf</ext-link><year>2013</year></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Korownyk</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>L.</given-names></name><name name-style="western"><surname>Young</surname><given-names>J.</given-names></name><etal/></person-group><article-title>PEER simplified chronic pain guideline: management of chronic low back, osteoarthritic, and neuropathic pain in primary care</article-title><source>Can Fam Physician</source><volume>68</volume><year>2022</year><fpage>179</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">35292455</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.46747/cfp.6803179</pub-id><pub-id pub-id-type="pmcid">PMC9833192</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Ferguson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Svendrovski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Katz</surname><given-names>J.</given-names></name></person-group><article-title>Association between multimorbid disease patterns and pain outcomes among a complex chronic care population in Canada</article-title><source>J&#160;Pain Res</source><volume>13</volume><year>2020</year><fpage>3045</fpage><lpage>3057</lpage><pub-id pub-id-type="pmid">33244262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/JPR.S269648</pub-id><pub-id pub-id-type="pmcid">PMC7685348</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Hanlon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hannigan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rodriguez-Perez</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Representation of people with comorbidity and multimorbidity in clinical trials of novel drug therapies: an individual-level participant data analysis</article-title><source>BMC Med</source><volume>17</volume><year>2019</year><fpage>201</fpage><pub-id pub-id-type="pmid">31711480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-019-1427-1</pub-id><pub-id pub-id-type="pmcid">PMC6849229</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>A.Y.L.</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>A.S.C.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>D.H.T.</given-names></name><etal/></person-group><article-title>Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study</article-title><source>Nat Commun</source><volume>14</volume><year>2023</year><fpage>5005</fpage><pub-id pub-id-type="pmid">37591833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-40637-8</pub-id><pub-id pub-id-type="pmcid">PMC10435503</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Daveluy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Micallef</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sanchez-Pena</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Ten-year trend of opioid and nonopioid analgesic use in the French adult population</article-title><source>Br J Clin Pharmacol</source><volume>87</volume><year>2021</year><fpage>555</fpage><lpage>564</lpage><pub-id pub-id-type="pmid">32496599</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.14415</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Use of non-steroidal anti-inflammatory drugs in US adults: changes over time and by demographic</article-title><source>Open Heart</source><volume>4</volume><year>2017</year><object-id pub-id-type="publisher-id">e000550</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/openhrt-2016-000550</pub-id><pub-id pub-id-type="pmcid">PMC5471872</pub-id><pub-id pub-id-type="pmid">28674622</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>G&#243;mez-Acebo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Dierssen-Sotos</surname><given-names>T.</given-names></name><name name-style="western"><surname>de Pedro</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Epidemiology of non-steroidal anti-inflammatory drugs consumption in Spain. The MCC-Spain study</article-title><source>BMC Public Health</source><volume>18</volume><year>2018</year><fpage>1134</fpage><pub-id pub-id-type="pmid">30241493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12889-018-6019-z</pub-id><pub-id pub-id-type="pmcid">PMC6150967</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Jayawardana</surname><given-names>S.</given-names></name><name name-style="western"><surname>Forman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Johnston-Webber</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Global consumption of prescription opioid analgesics between 2009-2019: a country-level observational study</article-title><source>EClinicalMedicine</source><volume>42</volume><year>2021</year><object-id pub-id-type="publisher-id">101198</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2021.101198</pub-id><pub-id pub-id-type="pmcid">PMC8599097</pub-id><pub-id pub-id-type="pmid">34820610</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Ju</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>L.</given-names></name><name name-style="western"><surname>Man</surname><given-names>K.K.C.</given-names></name><etal/></person-group><article-title>Global, regional, and national trends in opioid analgesic consumption from 2015 to 2019: a longitudinal study</article-title><source>Lancet Public Health</source><volume>7</volume><year>2022</year><fpage>e335</fpage><lpage>e346</lpage><pub-id pub-id-type="pmid">35366408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-2667(22)00013-5</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Busse</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kamaleldin</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Opioids for chronic noncancer pain: a systematic review and meta-analysis</article-title><source>JAMA</source><volume>320</volume><year>2018</year><fpage>2448</fpage><lpage>2460</lpage><pub-id pub-id-type="pmid">30561481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2018.18472</pub-id><pub-id pub-id-type="pmcid">PMC6583638</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Chou</surname><given-names>R.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Devine</surname><given-names>E.B.</given-names></name><etal/></person-group><article-title>The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop</article-title><source>Ann Intern Med</source><volume>162</volume><year>2015</year><fpage>276</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">25581257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M14-2559</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Cooper</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wiffen</surname><given-names>P.J.</given-names></name><etal/></person-group><article-title>Morphine for chronic neuropathic pain in adults</article-title><source>Cochrane Database Syst Rev</source><volume>5</volume><year>2017</year><fpage>CD011669</fpage><pub-id pub-id-type="pmid">28530786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD011669.pub2</pub-id><pub-id pub-id-type="pmcid">PMC6481499</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Els</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Hagtvedt</surname><given-names>R.</given-names></name><etal/></person-group><article-title>High-dose opioids for chronic non-cancer pain: an overview of Cochrane Reviews</article-title><source>Cochrane Database Syst Rev</source><volume>10</volume><year>2017</year><fpage>CD012299</fpage><pub-id pub-id-type="pmid">29084358</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD012299.pub2</pub-id><pub-id pub-id-type="pmcid">PMC6485814</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>R.V.</given-names></name><name name-style="western"><surname>Havens</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>S.L.</given-names></name></person-group><article-title>Gabapentin misuse, abuse and diversion: a systematic review</article-title><source>Addiction</source><volume>111</volume><year>2016</year><fpage>1160</fpage><lpage>1174</lpage><pub-id pub-id-type="pmid">27265421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/add.13324</pub-id><pub-id pub-id-type="pmcid">PMC5573873</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Gim&#233;nez-Campos</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Pimenta-Fermisson-Ramos</surname><given-names>P.</given-names></name><name name-style="western"><surname>D&#237;az-Cambronero</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Carbonell-Sanch&#237;s</surname><given-names>R.</given-names></name><name name-style="western"><surname>L&#243;pez-Briz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ru&#237;z-Garc&#237;a</surname><given-names>V.</given-names></name></person-group><article-title>A&#160;systematic review and meta-analysis of the effectiveness and adverse events of gabapentin and pregabalin for sciatica pain</article-title><source>Aten Primaria</source><volume>54</volume><year>2022</year><object-id pub-id-type="publisher-id">102144</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.aprim.2021.102144</pub-id><pub-id pub-id-type="pmcid">PMC8515246</pub-id><pub-id pub-id-type="pmid">34637958</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Meaadi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Obara</surname><given-names>I.</given-names></name><name name-style="western"><surname>Eldabe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nazar</surname><given-names>H.</given-names></name></person-group><article-title>The safety and efficacy of gabapentinoids in the management of neuropathic pain: a systematic review with meta-analysis of randomised controlled trials</article-title><source>Int J Clin Pharm</source><volume>45</volume><year>2023</year><fpage>556</fpage><lpage>565</lpage><pub-id pub-id-type="pmid">36848024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11096-022-01528-y</pub-id><pub-id pub-id-type="pmcid">PMC10250255</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Evoy</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Sadrameli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Contreras</surname><given-names>J.</given-names></name><name name-style="western"><surname>Covvey</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Peckham</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>M.D.</given-names></name></person-group><article-title>Abuse and misuse of pregabalin and gabapentin: a systematic review update</article-title><source>Drugs</source><volume>81</volume><year>2021</year><fpage>125</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">33215352</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40265-020-01432-7</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Wiffen</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Derry</surname><given-names>S.</given-names></name><name name-style="western"><surname>McQuay</surname><given-names>H.J.</given-names></name></person-group><article-title>Gabapentin for chronic neuropathic pain and fibromyalgia in adults</article-title><source>Cochrane Database Syst Rev</source><issue>3</issue><year>2011</year><fpage>CD007938</fpage><pub-id pub-id-type="pmid">21412914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD007938.pub2</pub-id><pub-id pub-id-type="pmcid">PMC4171034</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Baird</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>P.</given-names></name><name name-style="western"><surname>Colvin</surname><given-names>L.A.</given-names></name></person-group><article-title>Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers</article-title><source>Eur Addict Res</source><volume>20</volume><year>2014</year><fpage>115</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">24192603</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000355268</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Torrance</surname><given-names>N.</given-names></name><name name-style="western"><surname>Veluchamy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Trends in gabapentinoid prescribing, co-prescribing of opioids and benzodiazepines, and associated deaths in Scotland</article-title><source>Br J Anaesth</source><volume>125</volume><year>2020</year><fpage>159</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">32571568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bja.2020.05.017</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Donnan</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guthrie</surname><given-names>B.</given-names></name></person-group><article-title>Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis</article-title><source>BMC Nephrol</source><volume>18</volume><year>2017</year><fpage>256</fpage><pub-id pub-id-type="pmid">28764659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12882-017-0673-8</pub-id><pub-id pub-id-type="pmcid">PMC5540416</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Bhala</surname><given-names>N.</given-names></name><name name-style="western"><surname>Emberson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Merhi</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials</article-title><source>Lancet</source><volume>382</volume><year>2013</year><fpage>769</fpage><lpage>779</lpage><pub-id pub-id-type="pmid">23726390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(13)60900-9</pub-id><pub-id pub-id-type="pmcid">PMC3778977</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Bally</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dendukuri</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rich</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data</article-title><source>BMJ</source><volume>357</volume><year>2017</year><fpage>j1909</fpage><pub-id pub-id-type="pmid">28487435</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.j1909</pub-id><pub-id pub-id-type="pmcid">PMC5423546</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Castellsague</surname><given-names>J.</given-names></name><name name-style="western"><surname>Riera-Guardia</surname><given-names>N.</given-names></name><name name-style="western"><surname>Calingaert</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project)</article-title><source>Drug Saf</source><volume>35</volume><year>2012</year><fpage>1127</fpage><lpage>1146</lpage><pub-id pub-id-type="pmid">23137151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF03261999</pub-id><pub-id pub-id-type="pmcid">PMC3714137</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>McGettigan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Henry</surname><given-names>D.</given-names></name></person-group><article-title>Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies</article-title><source>PLoS Med</source><volume>8</volume><year>2011</year><object-id pub-id-type="publisher-id">e1001098</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.1001098</pub-id><pub-id pub-id-type="pmcid">PMC3181230</pub-id><pub-id pub-id-type="pmid">21980265</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Papaleontiou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Charles</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Outcomes associated with opioid use in the treatment of chronic noncancer pain in older adults: a systematic review and meta-analysis</article-title><source>J&#160;Am Geriatr Soc</source><volume>58</volume><year>2010</year><fpage>1353</fpage><lpage>1369</lpage><pub-id pub-id-type="pmid">20533971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1532-5415.2010.02920.x</pub-id><pub-id pub-id-type="pmcid">PMC3114446</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Schear</surname><given-names>S.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>L.X.</given-names></name><etal/></person-group><article-title>Multimorbidity and opioid prescribing in hospitalized older adults</article-title><source>J&#160;Palliat Med</source><volume>23</volume><year>2020</year><fpage>475</fpage><lpage>482</lpage><pub-id pub-id-type="pmid">31689152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/jpm.2019.0260</pub-id><pub-id pub-id-type="pmcid">PMC7643761</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Johnston</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Crilly</surname><given-names>M.</given-names></name><name name-style="western"><surname>Black</surname><given-names>C.</given-names></name><name name-style="western"><surname>Prescott</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Mercer</surname><given-names>S.W.</given-names></name></person-group><article-title>Defining and measuring multimorbidity: a systematic review of systematic reviews</article-title><source>Eur J Public Health</source><volume>29</volume><year>2019</year><fpage>182</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">29878097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurpub/cky098</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Ho</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Azcoaga-Lorenzo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Akbari</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Examining variation in the measurement of multimorbidity in research: a systematic review of 566 studies</article-title><source>Lancet Public Health</source><volume>6</volume><year>2021</year><fpage>e587</fpage><lpage>e597</lpage><pub-id pub-id-type="pmid">34166630</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-2667(21)00107-9</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Stirland</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Saavedra</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mullin</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Muniz-Terrera</surname><given-names>G.</given-names></name><name name-style="western"><surname>Russ</surname><given-names>T.C.</given-names></name></person-group><article-title>Measuring multimorbidity beyond counting diseases: systematic review of community and population studies and guide to index choice</article-title><source>BMJ</source><volume>368</volume><year>2020</year><fpage>m160</fpage><pub-id pub-id-type="pmid">32071114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.m160</pub-id><pub-id pub-id-type="pmcid">PMC7190061</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Ho</surname><given-names>I.S.S.</given-names></name><name name-style="western"><surname>Azcoaga-Lorenzo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Akbari</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Measuring multimorbidity in research: delphi consensus study</article-title><source>BMJ Med</source><volume>1</volume><year>2022</year><object-id pub-id-type="publisher-id">e000247</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjmed-2022-000247</pub-id><pub-id pub-id-type="pmcid">PMC9978673</pub-id><pub-id pub-id-type="pmid">36936594</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Rajbhandari-Thapa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Padilla</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>S.R.</given-names></name></person-group><article-title>Opioid-related hospitalization and its association with chronic diseases: findings from the National Inpatient Sample, 2011-2015</article-title><source>Prev Chronic Dis</source><volume>16</volume><year>2019</year><fpage>E157</fpage><pub-id pub-id-type="pmid">31775008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5888/pcd16.190169</pub-id><pub-id pub-id-type="pmcid">PMC6896831</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Page</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Bossuyt</surname><given-names>P.M.</given-names></name><etal/></person-group><article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title><source>BMJ</source><volume>372</volume><year>2021</year><fpage>n71</fpage><pub-id pub-id-type="pmid">33782057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmcid">PMC8005924</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Zorzela</surname><given-names>L.</given-names></name><name name-style="western"><surname>Loke</surname><given-names>Y.K.</given-names></name><name name-style="western"><surname>Ioannidis</surname><given-names>J.P.</given-names></name><etal/></person-group><article-title>PRISMA harms checklist: improving harms reporting in systematic reviews</article-title><source>BMJ</source><volume>352</volume><year>2016</year><fpage>i157</fpage><pub-id pub-id-type="pmid">26830668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.i157</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Chou</surname><given-names>R.</given-names></name><name name-style="western"><surname>Aronson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Atkins</surname><given-names>D.</given-names></name><etal/></person-group><article-title>AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program</article-title><source>J&#160;Clin Epidemiol</source><volume>63</volume><year>2010</year><fpage>502</fpage><lpage>512</lpage><pub-id pub-id-type="pmid">18823754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jclinepi.2008.06.007</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="book" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Peryer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Golder</surname><given-names>S.</given-names></name><name name-style="western"><surname>Junqueira</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Vohra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Loke</surname><given-names>Y.K.</given-names></name></person-group><part-title>Chapter 19: adverse effects</part-title><person-group person-group-type="editor"><name name-style="western"><surname>Higgins</surname><given-names>J.P.T.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chandler</surname><given-names>J.</given-names></name><etal/></person-group><source>Cochrane handbook for systematic reviews of interventions version 6.4 (updated august 2023)</source><year>2023</year><publisher-name>Cochrane</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://training.cochrane.org/handbook/current/chapter-19" id="intref0025">https://training.cochrane.org/handbook/current/chapter-19</ext-link></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>Thiese</surname><given-names>M.S.</given-names></name></person-group><article-title>Observational and interventional study design types; an overview</article-title><source>Biochem Med (Zagreb)</source><volume>24</volume><year>2014</year><fpage>199</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">24969913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.11613/BM.2014.022</pub-id><pub-id pub-id-type="pmcid">PMC4083571</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="book" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Golder</surname><given-names>S.</given-names></name></person-group><part-title>Adverse effects 2: searching for adverse effects</part-title><source>Cochrane adverse effects methods group</source><year>2017</year><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://training.cochrane.org/sites/training.cochrane.org/files/public/uploads/resources/Searching20for20adverse20effects_Su20Golder.pdf" id="intref0030">https://training.cochrane.org/sites/training.cochrane.org/files/public/uploads/resources/Searching20for20adverse20effects_Su20Golder.pdf</ext-link></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="book" id="sref54"><source>Covidence systematic review software</source><year>2024</year><publisher-name>Veritas Health Innovation</publisher-name><publisher-loc>Melbourne, Australia</publisher-loc><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.covidence.org" id="intref0035">www.covidence.org</ext-link></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="book" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Wells</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Shea</surname><given-names>B.</given-names></name><name name-style="western"><surname>O&#8217;Connell</surname><given-names>D.</given-names></name><etal/></person-group><part-title>The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses</part-title><year>2000</year><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp" id="intref0010c">https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp</ext-link></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>Pedersen</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Andreucci</surname><given-names>A.</given-names></name><name name-style="western"><surname>Thorlund</surname><given-names>J.B.</given-names></name><etal/></person-group><article-title>Prevalence, frequency, adverse events, and reasons for analgesic use in youth athletes: a systematic review and meta-analysis of 44,381 athletes</article-title><source>J&#160;Sci Med Sport</source><volume>25</volume><year>2022</year><fpage>810</fpage><lpage>819</lpage><pub-id pub-id-type="pmid">36100523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsams.2022.08.018</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name name-style="western"><surname>Yiu</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Vitharana</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gnjidic</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Patient risk factors for opioid-related adverse drug events in hospitalized patients: a systematic review</article-title><source>Pharmacotherapy</source><volume>42</volume><year>2022</year><fpage>194</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">35103999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/phar.2666</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name name-style="western"><surname>Sterne</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Hern&#225;n</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Reeves</surname><given-names>B.C.</given-names></name><etal/></person-group><article-title>ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions</article-title><source>BMJ</source><volume>355</volume><year>2016</year><fpage>i4919</fpage><pub-id pub-id-type="pmid">27733354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.i4919</pub-id><pub-id pub-id-type="pmcid">PMC5062054</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="book" id="sref59"><person-group person-group-type="author"><name name-style="western"><surname>McKenzie</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>S.E.</given-names></name></person-group><part-title>Chapter 12: synthesizing and presenting findings using other methods</part-title><person-group person-group-type="editor"><name name-style="western"><surname>Higgins</surname><given-names>J.P.T.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chandler</surname><given-names>J.</given-names></name><etal/></person-group><source>Cochrane handbook for systematic reviews of interventions version 6.4 (updated august 2023)</source><year>2023</year><publisher-name>Cochrane</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://training.cochrane.org/handbook/current/chapter-12" id="intref0040">https://training.cochrane.org/handbook/current/chapter-12</ext-link></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name name-style="western"><surname>Cano-Escalera</surname><given-names>G.</given-names></name><name name-style="western"><surname>Grana</surname><given-names>M.</given-names></name><name name-style="western"><surname>Irazusta</surname><given-names>J.</given-names></name><name name-style="western"><surname>Labayen</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gonzalez-Pinto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Besga</surname><given-names>A.</given-names></name></person-group><article-title>Mortality risks after two years in frail and pre-frail older adults admitted to hospital</article-title><source>J&#160;Clin Med</source><volume>12</volume><year>2023</year><fpage>3103</fpage><pub-id pub-id-type="pmid">37176544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm12093103</pub-id><pub-id pub-id-type="pmcid">PMC10179017</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name name-style="western"><surname>Gianni</surname><given-names>W.</given-names></name><name name-style="western"><surname>Madaio</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Ceci</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Transdermal buprenorphine for the treatment of chronic noncancer pain in the oldest old</article-title><source>J&#160;Pain Symptom Manage</source><volume>41</volume><year>2011</year><fpage>707</fpage><lpage>714</lpage><pub-id pub-id-type="pmid">21145700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpainsymman.2010.06.015</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name name-style="western"><surname>Glanz</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Binswanger</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Shetterly</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Narwaney</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name></person-group><article-title>Association between opioid dose variability and opioid overdose among adults prescribed long-term opioid therapy</article-title><source>JAMA Netw Open</source><volume>2</volume><year>2019</year><object-id pub-id-type="publisher-id">e192613</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2019.2613</pub-id><pub-id pub-id-type="pmcid">PMC6481879</pub-id><pub-id pub-id-type="pmid">31002325</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name name-style="western"><surname>H&#228;user</surname><given-names>W.</given-names></name><name name-style="western"><surname>Schubert</surname><given-names>T.</given-names></name><name name-style="western"><surname>Vogelmann</surname><given-names>T.</given-names></name><name name-style="western"><surname>Maier</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fitzcharles</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>T&#246;lle</surname><given-names>T.</given-names></name></person-group><article-title>All-cause mortality in patients with long-term opioid therapy compared with non-opioid analgesics for chronic non-cancer pain: a database study</article-title><source>BMC Med</source><volume>18</volume><year>2020</year><fpage>162</fpage><pub-id pub-id-type="pmid">32664901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-020-01644-4</pub-id><pub-id pub-id-type="pmcid">PMC7362543</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name name-style="western"><surname>Kessler</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gruschkus S</surname><given-names>K.</given-names></name><name name-style="western"><surname>Raju</surname><given-names>A.</given-names></name></person-group><article-title>Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: opioid-related adverse events and their impact on clinical and economic outcomes</article-title><source>Pharmacotherapy</source><volume>33</volume><year>2013</year><fpage>383</fpage><lpage>391</lpage><pub-id pub-id-type="pmid">23553809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/phar.1223</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Suh</surname><given-names>H.S.</given-names></name></person-group><article-title>A&#160;population-based study on the risk of prescription opioid abuse in patients with chronic opioid use and cost-effectiveness of prescription drug monitoring program using a patient simulation model in South Korea</article-title><source>Int J Drug Policy</source><volume>112</volume><year>2023</year><object-id pub-id-type="publisher-id">103953</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugpo.2023.103953</pub-id><pub-id pub-id-type="pmid">36645947</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Muo</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Kao</surname><given-names>C.H.</given-names></name></person-group><article-title>Atrial fibrillation is associated with morphine treatment in female breast cancer patients: a retrospective population-based time-dependent cohort study</article-title><source>Medicine (Baltimore)</source><volume>95</volume><year>2016</year><object-id pub-id-type="publisher-id">e3102</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000003102</pub-id><pub-id pub-id-type="pmcid">PMC4839934</pub-id><pub-id pub-id-type="pmid">26986153</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name name-style="western"><surname>Lobo</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Cochran</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C.H.</given-names></name><etal/></person-group><article-title>Associations between the specialty of opioid prescribers and opioid addiction, misuse, and overdose outcomes</article-title><source>Pain Med</source><volume>21</volume><year>2020</year><fpage>1871</fpage><lpage>1890</lpage><pub-id pub-id-type="pmid">31626295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/pm/pnz234</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name name-style="western"><surname>Maiti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sinvani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pisano</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Opiate prescribing in hospitalized older adults: patterns and outcomes</article-title><source>J&#160;Am Geriatr Soc</source><volume>66</volume><year>2018</year><fpage>70</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">29052224</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jgs.15127</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name name-style="western"><surname>Shafi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Collinsworth</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Copeland</surname><given-names>L.A.</given-names></name><etal/></person-group><article-title>Association of opioid-related adverse drug events with clinical and cost outcomes among surgical patients in a large integrated health care delivery system</article-title><source>JAMA Surg</source><volume>153</volume><year>2018</year><fpage>757</fpage><lpage>763</lpage><pub-id pub-id-type="pmid">29799927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamasurg.2018.1039</pub-id><pub-id pub-id-type="pmcid">PMC6142954</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name name-style="western"><surname>Thakarar</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lodi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Emergency department utilization among people living with HIV on chronic opioid therapy</article-title><source>J&#160;Int Assoc Provid AIDS Care</source><volume>20</volume><year>2021</year><object-id pub-id-type="publisher-id">23259582211010952</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/23259582211010952</pub-id><pub-id pub-id-type="pmcid">PMC8072919</pub-id><pub-id pub-id-type="pmid">33888001</pub-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name name-style="western"><surname>Thorell</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ranstad</surname><given-names>K.</given-names></name><name name-style="western"><surname>Midl&#246;v</surname><given-names>P.</given-names></name><name name-style="western"><surname>Borgquist</surname><given-names>L.</given-names></name><name name-style="western"><surname>Halling</surname><given-names>A.</given-names></name></person-group><article-title>Is use of fall risk-increasing drugs in an elderly population associated with an increased risk of hip fracture, after adjustment for multimorbidity level: a cohort study</article-title><source>BMC Geriatr</source><volume>14</volume><year>2014</year><fpage>131</fpage><pub-id pub-id-type="pmid">25475854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2318-14-131</pub-id><pub-id pub-id-type="pmcid">PMC4286212</pub-id></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name name-style="western"><surname>Weiner</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>El Ibrahimi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hendricks</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>Factors associated with opioid overdose after an initial opioid prescription</article-title><source>JAMA Netw Open</source><volume>5</volume><year>2022</year><object-id pub-id-type="publisher-id">e2145691</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2021.45691</pub-id><pub-id pub-id-type="pmcid">PMC8800077</pub-id><pub-id pub-id-type="pmid">35089351</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lian</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Prescription opioids are associated with higher mortality in patients diagnosed with sepsis: a retrospective cohort study using electronic health records</article-title><source>PLoS One</source><volume>13</volume><year>2018</year><object-id pub-id-type="publisher-id">e0190362</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0190362</pub-id><pub-id pub-id-type="pmcid">PMC5749778</pub-id><pub-id pub-id-type="pmid">29293575</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name name-style="western"><surname>Zemedikun</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nirantharakumar</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Comorbidity phenotypes and risk of mortality in patients with osteoarthritis in the UK: a latent class analysis</article-title><source>Arthritis Res Ther</source><volume>24</volume><year>2022</year><fpage>231</fpage><pub-id pub-id-type="pmid">36229868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13075-022-02909-4</pub-id><pub-id pub-id-type="pmcid">PMC9559033</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name name-style="western"><surname>Humes</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Fleming</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Spiller</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>West</surname><given-names>J.</given-names></name></person-group><article-title>Concurrent drug use and the risk of perforated colonic diverticular disease: a population-based case-control study</article-title><source>Gut</source><volume>60</volume><year>2011</year><fpage>219</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">20940283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gut.2010.217281</pub-id></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name name-style="western"><surname>Abraham</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Castillo</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Hartman</surname><given-names>C.</given-names></name></person-group><article-title>National mortality following upper gastrointestinal or cardiovascular events in older veterans with recent nonsteroidal anti-inflammatory drug use</article-title><source>Aliment Pharmacol Ther</source><volume>28</volume><year>2008</year><fpage>97</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">18397385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2036.2008.03706.x</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>S.-K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Won</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Impact of anti-rheumatic treatment on cardiovascular risk in Asian patients with rheumatoid arthritis</article-title><source>Semin Arthritis Rheum</source><volume>47</volume><year>2018</year><fpage>501</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">28863826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semarthrit.2017.08.002</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name name-style="western"><surname>Gallagher</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Castro</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fava</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study</article-title><source>Am J Psychiatry</source><volume>169</volume><year>2012</year><fpage>1065</fpage><lpage>1072</lpage><pub-id pub-id-type="pmid">23032386</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ajp.2012.11091325</pub-id><pub-id pub-id-type="pmcid">PMC3787520</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name name-style="western"><surname>Glassou</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Kristensen</surname><given-names>N.</given-names></name><name name-style="western"><surname>M&#248;ller</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Erikstrup</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>A.B.</given-names></name></person-group><article-title>Impact of preadmission anti-inflammatory drug use on the risk of RBC transfusion in elderly hip fracture patients: a Danish nationwide cohort study, 2005-2016</article-title><source>Transfusion</source><volume>59</volume><year>2019</year><fpage>935</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">30610758</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/trf.15110</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name name-style="western"><surname>Hall</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Mangram</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Barletta</surname><given-names>J.F.</given-names></name></person-group><article-title>Identification of risk factors for acute kidney injury from intravenous ketorolac in geriatric trauma patients</article-title><source>World J Surg</source><volume>46</volume><year>2022</year><fpage>98</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">34553259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00268-021-06320-z</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Hildebrand</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Dixon</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A&#160;matched case-control study to assess the association between non-steroidal anti-inflammatory drug use and thrombotic microangiopathy</article-title><source>PLoS One</source><volume>13</volume><year>2018</year><object-id pub-id-type="publisher-id">e0202801</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0202801</pub-id><pub-id pub-id-type="pmcid">PMC6108507</pub-id><pub-id pub-id-type="pmid">30142223</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name name-style="western"><surname>Stockl</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cyprien</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>E.Y.</given-names></name></person-group><article-title>Gastrointestinal bleeding rates among managed care patients newly started on cox-2 inhibitors or nonselective NSAIDs</article-title><source>J&#160;Manag Care Pharm</source><volume>11</volume><year>2005</year><fpage>550</fpage><lpage>558</lpage><pub-id pub-id-type="pmid">16137212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18553/jmcp.2005.11.7.550</pub-id><pub-id pub-id-type="pmcid">PMC10438022</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name name-style="western"><surname>Yamanashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Comp</surname><given-names>K.R.</given-names></name><etal/></person-group><article-title>Anti-inflammatory medication use associated with reduced delirium risk and all-cause mortality: a retrospective cohort study</article-title><source>J&#160;Psychosom Res</source><volume>168</volume><year>2023</year><object-id pub-id-type="publisher-id">111212</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpsychores.2023.111212</pub-id><pub-id pub-id-type="pmid">36963165</pub-id></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Inouye</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Marcantonio</surname><given-names>E.R.</given-names></name><etal/></person-group><article-title>Perioperative gabapentin use and in-hospital adverse clinical events among older adults after major surgery</article-title><source>JAMA Intern Med</source><volume>182</volume><year>2022</year><fpage>1117</fpage><lpage>1127</lpage><pub-id pub-id-type="pmid">36121671</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamainternmed.2022.3680</pub-id><pub-id pub-id-type="pmcid">PMC9486639</pub-id></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name name-style="western"><surname>Bonnesen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ehrenstein</surname><given-names>V.</given-names></name><name name-style="western"><surname>S&#248;rensen</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Lash</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>M.</given-names></name></person-group><article-title>Impact of hemoglobin A1c level on the association between non-steroidal anti-inflammatory drug use and cardiovascular events in patients with type 2 diabetes: a population-based cohort study</article-title><source>Pharmacoepidemiol Drug Saf</source><volume>32</volume><year>2023</year><fpage>1233</fpage><lpage>1243</lpage><pub-id pub-id-type="pmid">37294526</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pds.5652</pub-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name name-style="western"><surname>Podesser</surname><given-names>F.</given-names></name><name name-style="western"><surname>Weninger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Marksteiner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Canazei</surname><given-names>M.</given-names></name></person-group><article-title>Short-term medication effect on fall risk in multimorbid inpatients with dementia</article-title><source>Gerontology</source><volume>70</volume><year>2024</year><fpage>620</fpage><lpage>629</lpage><pub-id pub-id-type="pmid">38626732</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000538074</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name name-style="western"><surname>Hadi</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>McHugh</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Closs</surname><given-names>S.J.</given-names></name></person-group><article-title>Impact of chronic pain on patients' quality of life: a comparative mixed-methods study</article-title><source>J&#160;Patient Exp</source><volume>6</volume><year>2019</year><fpage>133</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">31218259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2374373518786013</pub-id><pub-id pub-id-type="pmcid">PMC6558939</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name name-style="western"><surname>Breivik</surname><given-names>H.</given-names></name><name name-style="western"><surname>Collett</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ventafridda</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gallacher</surname><given-names>D.</given-names></name></person-group><article-title>Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment</article-title><source>Eur J Pain</source><volume>10</volume><year>2006</year><fpage>287</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">16095934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejpain.2005.06.009</pub-id></element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>E.</given-names></name><name name-style="western"><surname>Salisbury</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sasseville</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bayliss</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fortin</surname><given-names>M.</given-names></name></person-group><article-title>A&#160;core outcome set for multimorbidity research (COSmm)</article-title><source>Ann Fam Med</source><volume>16</volume><year>2018</year><fpage>132</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">29531104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1370/afm.2178</pub-id><pub-id pub-id-type="pmcid">PMC5847351</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name name-style="western"><surname>Peppin</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Cheatle</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Kirsh</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>McCarberg</surname><given-names>B.H.</given-names></name></person-group><article-title>The complexity model: a novel approach to improve chronic pain care</article-title><source>Pain Med</source><volume>16</volume><year>2015</year><fpage>653</fpage><lpage>666</lpage><pub-id pub-id-type="pmid">25752874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/pme.12621</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kingswood</surname><given-names>C.</given-names></name><name name-style="western"><surname>Street</surname><given-names>M.</given-names></name></person-group><article-title>Pharmacokinetics of opioids in renal dysfunction</article-title><source>Clin Pharmacokinet</source><volume>31</volume><year>1996</year><fpage>410</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">8968655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-199631060-00002</pub-id></element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name name-style="western"><surname>Wasan</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Michna</surname><given-names>E.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>R.R.</given-names></name><etal/></person-group><article-title>Psychiatric comorbidity is associated prospectively with diminished opioid analgesia and increased opioid misuse in patients with chronic low back pain</article-title><source>Anesthesiology</source><volume>123</volume><year>2015</year><fpage>861</fpage><lpage>872</lpage><pub-id pub-id-type="pmid">26375824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ALN.0000000000000768</pub-id><pub-id pub-id-type="pmcid">PMC4573512</pub-id></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name name-style="western"><surname>Senaratne</surname><given-names>D.N.S.</given-names></name><name name-style="western"><surname>Thakkar</surname><given-names>B.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Hales</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Marryat</surname><given-names>L.</given-names></name><name name-style="western"><surname>Colvin</surname><given-names>L.A.</given-names></name></person-group><article-title>The impact of adverse childhood experiences on multimorbidity: a systematic review and meta-analysis</article-title><source>BMC Med</source><volume>22</volume><year>2024</year><fpage>315</fpage><pub-id pub-id-type="pmid">39143489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-024-03505-w</pub-id><pub-id pub-id-type="pmcid">PMC11325707</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name name-style="western"><surname>Antoniou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lambourg</surname><given-names>E.</given-names></name><name name-style="western"><surname>Steele</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Colvin</surname><given-names>L.A.</given-names></name></person-group><article-title>The effect of adverse childhood experiences on chronic pain and major depression in adulthood: a systematic review and meta-analysis</article-title><source>Br J Anaesth</source><volume>130</volume><year>2023</year><fpage>729</fpage><lpage>746</lpage><pub-id pub-id-type="pmid">37087334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bja.2023.03.008</pub-id><pub-id pub-id-type="pmcid">PMC10251130</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name name-style="western"><surname>Merrick</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Ford</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Haegerich</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>T.</given-names></name></person-group><article-title>Adverse childhood experiences increase risk for prescription opioid misuse</article-title><source>J&#160;Prim Prev</source><volume>41</volume><year>2020</year><fpage>139</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">31989435</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10935-020-00578-0</pub-id><pub-id pub-id-type="pmcid">PMC10976456</pub-id></element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name name-style="western"><surname>Whitty</surname><given-names>C.J.M.</given-names></name><name name-style="western"><surname>MacEwen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Goddard</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Rising to the challenge of multimorbidity</article-title><source>BMJ</source><volume>368</volume><year>2020</year><fpage>l6964</fpage><pub-id pub-id-type="pmid">31907164</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.l6964</pub-id><pub-id pub-id-type="pmcid">PMC7190283</pub-id></element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name name-style="western"><surname>Jani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Birlie Yimer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sheppard</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lunt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dixon</surname><given-names>W.G.</given-names></name></person-group><article-title>Time trends and prescribing patterns of opioid drugs in UK primary care patients with non-cancer pain: a retrospective cohort study</article-title><source>PLoS Med</source><volume>17</volume><year>2020</year><object-id pub-id-type="publisher-id">e1003270</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.1003270</pub-id><pub-id pub-id-type="pmcid">PMC7561110</pub-id><pub-id pub-id-type="pmid">33057368</pub-id></element-citation></ref><ref id="bib98"><label>98</label><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name name-style="western"><surname>Guy</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bohm</surname><given-names>M.K.</given-names></name><etal/></person-group><article-title>Vital signs: changes in opioid prescribing in the United States, 2006&#8211;2015</article-title><source>MMWR Morb Mortal Wkly Rep</source><volume>66</volume><year>2017</year><fpage>697</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">28683056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm6626a4</pub-id><pub-id pub-id-type="pmcid">PMC5726238</pub-id></element-citation></ref><ref id="bib99"><label>99</label><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name name-style="western"><surname>Torrance</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mansoor</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Association of opioid prescribing practices with chronic pain and benzodiazepine co-prescription: a primary care data linkage study</article-title><source>Br J Anaesth</source><volume>120</volume><year>2018</year><fpage>1345</fpage><lpage>1355</lpage><pub-id pub-id-type="pmid">29793600</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bja.2018.02.022</pub-id></element-citation></ref><ref id="bib100"><label>100</label><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name name-style="western"><surname>Riva</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Noor</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Predictors of prolonged opioid use after initial prescription for acute musculoskeletal injuries in adults: a systematic review and meta-analysis of observational studies</article-title><source>Ann Intern Med</source><volume>173</volume><year>2020</year><fpage>721</fpage><lpage>729</lpage><pub-id pub-id-type="pmid">32805130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M19-3600</pub-id></element-citation></ref><ref id="bib101"><label>101</label><element-citation publication-type="journal" id="sref101"><person-group person-group-type="author"><name name-style="western"><surname>Fritz</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>King</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>McAdams-Marx</surname><given-names>C.</given-names></name></person-group><article-title>Associations between early care decisions and the risk for long-term opioid use for patients with low back pain with a new physician consultation and initiation of opioid therapy</article-title><source>Clin J Pain</source><volume>34</volume><year>2018</year><fpage>552</fpage><lpage>558</lpage><pub-id pub-id-type="pmid">29135698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/AJP.0000000000000571</pub-id></element-citation></ref><ref id="bib102"><label>102</label><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name name-style="western"><surname>Delgado</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Meisel</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>National variation in opioid prescribing and risk of prolonged use for opioid-naive patients treated in the emergency department for ankle sprains</article-title><source>Ann Emerg Med</source><volume>72</volume><year>2018</year><fpage>389</fpage><lpage>400.e1</lpage><pub-id pub-id-type="pmid">30054152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annemergmed.2018.06.003</pub-id><pub-id pub-id-type="pmcid">PMC6319263</pub-id></element-citation></ref><ref id="bib103"><label>103</label><element-citation publication-type="journal" id="sref103"><person-group person-group-type="author"><name name-style="western"><surname>Dufour</surname><given-names>S.</given-names></name><name name-style="western"><surname>Banaag</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schoenfeld</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Koehlmoos</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>J.C.</given-names></name></person-group><article-title>Diagnostic profiles associated with long-term opioid therapy in active duty servicemembers</article-title><source>PM R</source><volume>16</volume><year>2024</year><fpage>14</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">37162022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pmrj.12994</pub-id><pub-id pub-id-type="pmcid">PMC10786620</pub-id></element-citation></ref><ref id="bib104"><label>104</label><element-citation publication-type="journal" id="sref104"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Siddiqui</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Gossop</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wyller</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Kristoffersen</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Lundqvist</surname><given-names>C.</given-names></name></person-group><article-title>The patterns and burden of multimorbidity in geriatric patients with prolonged use of addictive medications</article-title><source>Aging Clin Exp Res</source><volume>33</volume><year>2021</year><fpage>2857</fpage><lpage>2864</lpage><pub-id pub-id-type="pmid">33599959</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40520-021-01791-5</pub-id><pub-id pub-id-type="pmcid">PMC8531043</pub-id></element-citation></ref><ref id="bib105"><label>105</label><element-citation publication-type="journal" id="sref105"><person-group person-group-type="author"><name name-style="western"><surname>Els</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Kunyk</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Adverse events associated with medium-and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane Reviews</article-title><source>Cochrane Database Syst Rev</source><volume>10</volume><year>2017</year><fpage>CD012509</fpage><pub-id pub-id-type="pmid">29084357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD012509.pub2</pub-id><pub-id pub-id-type="pmcid">PMC6485910</pub-id></element-citation></ref><ref id="bib106"><label>106</label><element-citation publication-type="journal" id="sref106"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sites</surname><given-names>B.D.</given-names></name></person-group><article-title>Prescription opioid use among adults with mental health disorders in the United States</article-title><source>J&#160;Am Board Fam Med</source><volume>30</volume><year>2017</year><fpage>407</fpage><lpage>417</lpage><pub-id pub-id-type="pmid">28720623</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3122/jabfm.2017.04.170112</pub-id></element-citation></ref><ref id="bib107"><label>107</label><element-citation publication-type="journal" id="sref107"><person-group person-group-type="author"><name name-style="western"><surname>Edlund</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Devries</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Braden</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>M.D.</given-names></name></person-group><article-title>Trends in use of opioids for chronic noncancer pain among individuals with mental health and substance use disorders: the TROUP study</article-title><source>Clin J Pain</source><volume>26</volume><year>2010</year><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">20026946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/AJP.0b013e3181b99f35</pub-id><pub-id pub-id-type="pmcid">PMC2917238</pub-id></element-citation></ref><ref id="bib108"><label>108</label><element-citation publication-type="journal" id="sref108"><person-group person-group-type="author"><name name-style="western"><surname>Ritchie</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Garrett</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Miaskowski</surname><given-names>C.</given-names></name></person-group><article-title>Unintended consequences of opioid regulations in older adults with multiple chronic conditions</article-title><source>Gerontologist</source><volume>60</volume><year>2020</year><fpage>1343</fpage><lpage>1352</lpage><pub-id pub-id-type="pmid">32222760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/geront/gnaa016</pub-id><pub-id pub-id-type="pmcid">PMC7491430</pub-id></element-citation></ref><ref id="bib109"><label>109</label><element-citation publication-type="journal" id="sref109"><person-group person-group-type="author"><name name-style="western"><surname>Qureshi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mayo-Wilson</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rittiphairoj</surname><given-names>T.</given-names></name><name name-style="western"><surname>McAdams-DeMarco</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guallar</surname><given-names>E.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name></person-group><article-title>Harms in Systematic Reviews Paper 2: methods used to assess harms are neglected in systematic reviews of gabapentin</article-title><source>J&#160;Clin Epidemiol</source><volume>143</volume><year>2022</year><fpage>212</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">34742789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jclinepi.2021.10.024</pub-id><pub-id pub-id-type="pmcid">PMC9875742</pub-id></element-citation></ref><ref id="bib110"><label>110</label><element-citation publication-type="journal" id="sref110"><person-group person-group-type="author"><name name-style="western"><surname>Zorzela</surname><given-names>L.</given-names></name><name name-style="western"><surname>Golder</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Quality of reporting in systematic reviews of adverse events: systematic review</article-title><source>BMJ</source><volume>348</volume><year>2014</year><fpage>f7668</fpage><pub-id pub-id-type="pmid">24401468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.f7668</pub-id><pub-id pub-id-type="pmcid">PMC3898583</pub-id></element-citation></ref><ref id="bib111"><label>111</label><element-citation publication-type="journal" id="sref111"><person-group person-group-type="author"><name name-style="western"><surname>Charlson</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Pompei</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ales</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>MacKenzie</surname><given-names>C.R.</given-names></name></person-group><article-title>A&#160;new method of classifying prognostic comorbidity in longitudinal studies: development and validation</article-title><source>J&#160;Chronic Dis</source><volume>40</volume><year>1987</year><fpage>373</fpage><lpage>383</lpage><pub-id pub-id-type="pmid">3558716</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0021-9681(87)90171-8</pub-id></element-citation></ref><ref id="bib112"><label>112</label><element-citation publication-type="journal" id="sref112"><person-group person-group-type="author"><name name-style="western"><surname>Huntley</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Purdy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Valderas</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Salisbury</surname><given-names>C.</given-names></name></person-group><article-title>Measures of multimorbidity and morbidity burden for use in primary care and community settings: a systematic review and guide</article-title><source>Ann Fam Med</source><volume>10</volume><year>2012</year><fpage>134</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">22412005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1370/afm.1363</pub-id><pub-id pub-id-type="pmcid">PMC3315139</pub-id></element-citation></ref><ref id="bib113"><label>113</label><element-citation publication-type="journal" id="sref113"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Koh</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>E.Q.</given-names></name><etal/></person-group><article-title>Systematic review on the instruments used for measuring the association of the level of multimorbidity and clinically important outcomes</article-title><source>BMJ Open</source><volume>11</volume><year>2021</year><object-id pub-id-type="publisher-id">e041219</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2020-041219</pub-id><pub-id pub-id-type="pmcid">PMC8103380</pub-id><pub-id pub-id-type="pmid">33952533</pub-id></element-citation></ref><ref id="bib114"><label>114</label><element-citation publication-type="journal" id="sref114"><person-group person-group-type="author"><name name-style="western"><surname>Abdel</surname><given-names>Shaheed C.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Dmitritchenko</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The efficacy and safety of paracetamol for pain relief: an overview of systematic reviews</article-title><source>Med J Aust</source><volume>214</volume><year>2021</year><fpage>324</fpage><lpage>331</lpage><pub-id pub-id-type="pmid">33786837</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5694/mja2.50992</pub-id></element-citation></ref><ref id="bib115"><label>115</label><element-citation publication-type="journal" id="sref115"><person-group person-group-type="author"><name name-style="western"><surname>Kaur</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nakafero</surname><given-names>G.</given-names></name><name name-style="western"><surname>Abhishek</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mallen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name></person-group><article-title>Incidence of side effects associated with acetaminophen in people aged 65 years or more: a prospective cohort study using data from the Clinical Practice Research Datalink</article-title><source>Arthritis Care Res (Hoboken)</source><year>2024</year><pub-id pub-id-type="doi">10.1002/acr.25471</pub-id><comment>Advance Access published on Nov 24</comment><pub-id pub-id-type="pmcid">PMC12038216</pub-id><pub-id pub-id-type="pmid">39582150</pub-id></element-citation></ref><ref id="bib116"><label>116</label><element-citation publication-type="journal" id="sref116"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Vase</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hooten</surname><given-names>W.M.</given-names></name></person-group><article-title>Chronic pain: an update on burden, best practices, and new advances</article-title><source>Lancet</source><volume>397</volume><year>2021</year><fpage>2082</fpage><lpage>2097</lpage><pub-id pub-id-type="pmid">34062143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00393-7</pub-id></element-citation></ref><ref id="bib117"><label>117</label><element-citation publication-type="journal" id="sref117"><person-group person-group-type="author"><name name-style="western"><surname>Villalba-Moreno</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Alfaro-Lara</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Rodriguez-Perez</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Association between drug burden index and functional and cognitive function in patients with multimorbidity</article-title><source>Curr Pharm Des</source><volume>24</volume><year>2018</year><fpage>3384</fpage><lpage>3391</lpage><pub-id pub-id-type="pmid">29589542</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1381612824666180327154239</pub-id></element-citation></ref><ref id="bib118"><label>118</label><element-citation publication-type="journal" id="sref118"><person-group person-group-type="author"><name name-style="western"><surname>Gebresillassie</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Kassaw</surname><given-names>A.T.</given-names></name></person-group><article-title>Exploring the impact of medication regimen complexity on health-related quality of life in patients with multimorbidity</article-title><source>J&#160;Clin Pharm Ther</source><volume>2023</volume><year>2023</year><object-id pub-id-type="publisher-id">1744472</object-id></element-citation></ref><ref id="bib119"><label>119</label><element-citation publication-type="journal" id="sref119"><person-group person-group-type="author"><name name-style="western"><surname>Vill&#233;n</surname><given-names>N.</given-names></name><name name-style="western"><surname>Guisado-Clavero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Bertol&#237;n</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Multimorbidity patterns, polypharmacy and their association with liver and kidney abnormalities in people over 65 years of age: a longitudinal study</article-title><source>BMC Geriatr</source><volume>20</volume><year>2020</year><fpage>206</fpage><pub-id pub-id-type="pmid">32532213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12877-020-01580-1</pub-id><pub-id pub-id-type="pmcid">PMC7291454</pub-id></element-citation></ref><ref id="bib120"><label>120</label><element-citation publication-type="journal" id="sref120"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Panagiotakos</surname><given-names>D.</given-names></name></person-group><article-title>Real-world data: a brief review of the methods, applications, challenges and opportunities</article-title><source>BMC Med Res Methodol</source><volume>22</volume><year>2022</year><fpage>287</fpage><pub-id pub-id-type="pmid">36335315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12874-022-01768-6</pub-id><pub-id pub-id-type="pmcid">PMC9636688</pub-id></element-citation></ref><ref id="bib121"><label>121</label><element-citation publication-type="journal" id="sref121"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>E.L.</given-names></name></person-group><article-title>Target trial emulation to improve causal inference from observational data: what, why, and how?</article-title><source>J&#160;Am Soc Nephrol</source><volume>34</volume><year>2023</year><fpage>1305</fpage><lpage>1314</lpage><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://evidence.nihr.ac.uk/collection/making-sense-of-the-evidence-multiple-long-term-conditions-multimorbidity/" id="intref0010d">https://evidence.nihr.ac.uk/collection/making-sense-of-the-evidence-multiple-long-term-conditions-multimorbidity/</ext-link><pub-id pub-id-type="doi">10.3310/collection_45881</pub-id><pub-id pub-id-type="pmid">37131279</pub-id><pub-id pub-id-type="pmcid">PMC10400102</pub-id></element-citation></ref><ref id="bib122"><label>122</label><element-citation publication-type="journal" id="sref122"><person-group person-group-type="author"><name name-style="western"><surname>Imison</surname><given-names>C.</given-names></name></person-group><article-title>Multiple long-term conditions (multimorbidity): making sense of the evidence</article-title><source>Natl Inst Health Res</source><year>2021</year><pub-id pub-id-type="doi">10.3310/collection_45881</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0260">The following is the Supplementary data to this article:<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Multimedia component 1</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"><alt-text>Multimedia component 1</alt-text></media></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgements</title><p id="p0255">We are very grateful to Scott McGregor (SM), an academic librarian from the University of Dundee, for assistance in devising and running the literature search strategy as outlined. We would like to thank our Patient &amp; Public Involvement group for their contributions and continued support.</p></ack><fn-group><fn id="appsec2" fn-type="supplementary-material"><label>Appendix A</label><p id="p0265">Supplementary data to this article can be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.bja.2025.02.012" id="intref0010">https://doi.org/10.1016/j.bja.2025.02.012</ext-link>.</p></fn></fn-group></back></article></pmc-articleset>